Schizophrenia Research

Introduction
pp. 3-5(3)
Author: DeLisi L.E.

Schizophrenia as a lifetime disorder: the early course from onset until five years after first admission
pp. 7-7(1)
Authors: Hafner H.; an der Heiden W.

Schizophrenia as a lifetime disorder: the long-term course and outcome of schizophrenia
pp. 7-7(1)
Authors: an der Heiden W.; Hafner H.

First-episode schizophrenia, a naturalistic 10 year follow-up study
pp. 7-8(2)
Authors: De Hert M.; Peuskens J.

Follow-up of first episode psychotic patients treated on a specialized ward
pp. 8-8(1)
Authors: Merlo M.C.G.; Panhuber I.; Gekle W.; Berger G.

Duration of untreated psychosis and outcome in a 10 year follow-up cohort of schizophrenic subjects
pp. 8-8(1)
Authors: Hopkins R.S.; White C.J.; Montague L.; Lewis S.W.

Depression in schizophrenia: from the prodromal phase of the first psychotic episode until 5 years after first hospitalisation
pp. 8-9(2)
Authors: Maurer K.; Hafner H.

Diagnostic stability of first onset psychoses: implications for epidemiology
pp. 9-9(1)
Authors: Amin S.; Brewin J.; Singh S.P.; Harrison G.L.; Medley I.; Kwiecinski R.

Longterm course of schizophrenia; implications for treatment, research and policies after 1996
pp. 9-9(1)
Author: Slooff C.J.

Reliability, validity and utility of the health of the nation outcome scale (HoNOS) in Australian adult psychiatric services
pp. 9-10(2)
Authors: Hope J.D.; Trauer T.; Keks N.A.

The hillside study of risk and early detection in schizophrenia: early findings
pp. 10-10(1)
Authors: Cornblatt B.; Obuchowski M.

Early detection and intervention in first episode psychosis--preliminary data from the danish comparison site
pp. 10-10(1)
Authors: Simonsen E.; Haabr U.H.; Dahl A.; Olsen L.R.

One hundred young people (aged 16-24) at risk for developing schizophrenia
pp. 10-11(2)
Authors: Hodges A.; Byrne M.; Grant E.; Johnstone E.

The predictors of schizophrenia in the 1966 Northern Finland birth cohort study
pp. 11-11(1)
Authors: Isohanni M.; Rantakallio P.; Jones P.; Jarvelin M.R.; Isohanni I.; Makikyro T.; Moring J.

Predicting schizophrenia in teenagers: pessimistic results from the British 1946 birth cohort
pp. 11-11(1)
Authors: Jones P.B.; van Os J.J.

Developmental trajectories towards adult schizophrenia: A multi-level growth curve analysis of the 1946 British MRC National survey of health and development general population birth cohort
pp. 11-12(2)
Authors: Croudace T.J.; Jones P.

Population shifts, paradigm shifts and the cause of schizophrenia
pp. 12-12(1)
Author: Jones P.B.

Social deprivation at birth and increased risk of psychosis: evidence from a first episode study
pp. 12-12(1)
Authors: Harrison G.; Glazebrook C.; Page K.; Brewin J.

Is household crowding a risk factor for schizophrenia?
pp. 12-13(2)
Authors: Torrey E.F.; Yolken R.H.

Life events, family history and ethnicity in schizophrenia
pp. 13-13(1)
Authors: Hutchinson G.; Takei N.; Bebbington P.; Wilkins S.; Mallett M.R.; Burnett R.; Leff J.; Murray R.M.

Familial and non-familial risk factors for schizophrenia: a population-based study
pp. 13-13(1)
Authors: Mortensen P.B.; Pedersen C.B.; Westergaard T.; Wohlfahrt J.; Ewald H.; Mors O.; Andersen P.K.; Melbye M.

Incidence rates for schizophrenia and migration. Another view of the excess risk for schizophrenia among African-Caribbeans in Britain
pp. 13-14(2)
Authors: Leff J.; Mallett M.R.; Bhugra D.; Mahy G.E.; Hutchinson G.; Takei N.

Adverse pregnancy outcomes among schizophrenic women
pp. 14-14(1)
Authors: Bennedsen B.E.; Mortensen P.B.; Olesen A.V.

Chronic fetal hypoxia and other obstetric risk factors for psychotic illness: a replication study
pp. 14-14(1)
Authors: Buka S.L.; Goldstein J.M.; Seidman L.J.; Zornberg G.L.; Denny L.R.; Tsuang M.T.

Obstetric recall in mothers to schizophrenic patients
pp. 14-15(2)
Authors: Cantor-Graae E.; Cardenal S.; Ismail B.T.; McNeil T.F.

New evidence regarding history of obstetric complications (OCs) in schizophrenic patients and their siblings
pp. 15-15(1)
Authors: Cantor-Graae E.; Ismail B.T.; Cardenal S.; Nordstrom L.; McNeil T.F.

Schizophrenia, obstetric complications, and place of birth
pp. 15-15(1)
Authors: Eaton W.W.; Mortensen P.B.; Frydenberg M.

Aberrations in intra-unterine growth as independent risk factors for schizophrenia
pp. 15-15(1)
Authors: Hultman C.M.; Cnattingius S.

Schizophrenia as a long-term outcome of perinatal brain damage: a 28 year follow-up of the 1966 North Finland general population birth cohort
pp. 16-16(1)
Authors: Jones P.B.; Rantakallio P.; Hartikainen A.-L.; Isohanni M.; Sipila P.; Jarvelin M.-R.

Psychiatric illness and experience of obstetric complications
pp. 16-16(1)
Authors: Marcelis M.; van Os J.; Sham P.; Jones P.; Gilvarry C.; Cannon M.; McKenzie K.; Murray R.

Obstetric complications, treatment response and brain morphology in adult onset and early onset females with schizophrenia
pp. 16-17(2)
Authors: Smith G.N.; Dhillon S.; Kopala L.C.; Flynn S.W.; Lapointe J.S.; MacEwan G.W.; Altman S.; Schneider T.; Falkai P.; Honer W.G.

Low birth weight in schizophrenia: incidence and clinical implications
pp. 17-17(1)
Authors: Smith G.N.; McCarthy N.; Meistrich B.; Kopala L.C.; Flynn S.W.; Lapointe J.S.; MacEwan G.W.; Altman S.; Honer W.G.

Prenatal exposure to maternal stress and later schizophrenia: the May 1940 invasion of The Netherlands
pp. 17-17(1)
Authors: van Os J.; Selten J.P.

Schizophrenia following prenatal rubella exposure: gestational timing and diagnostic specificity
pp. 17-18(2)
Authors: Brown A.S.; Susser E.S.; Cohen P.; Greenwald S.

Childhood illnesses and adult psychosis in a national birth cohort
pp. 18-18(1)
Authors: Leask S.J.; Done D.J.; Crow T.J.

Influenza epidemics and the incidence of schizophrenia, affective disorders and mental retardation: further data from Western Australia
pp. 18-18(1)
Authors: Morgan V.; Castle D.; Page A.; Montgomery P.; Gurrin L.; Burton P.; Fazio S.; Jablensky A.

Influenza rates, birth order and risk of schizophrenia: a population-based cohort study
pp. 18-18(1)
Authors: Westergaard T.; Mortensen P.B.; Pedersen C.B.; Wohlfahrt J.; Melbye M.

Prenatal exposure to 1957 influenza pandemic and non-affective psychosis in The Netherlands
pp. 19-19(1)
Authors: Selten J.P.; Brown A.S.; Slaets J.P.J.; Susser E.; Kahn R.S.

Borna disease virus in Caribbean immigrants to the Netherlands, diagnosed with schizophrenia
pp. 19-19(1)
Authors: Selten J.P.; van Loon A.M.; van Vliet K.; Pleyte W.; Hoek H.W.; Kahn R.S.

Affective psychoses and the influenza epidemics of 1954, 1957, and 1959
pp. 19-19(1)
Authors: Welham J.; McGrath J.; Pemberton M.

Reproductive pathology in women with schizophrenia and affective psychoses
pp. 20-20(1)
Authors: Jablensky A.; Zubrick S.; Morgan V.; Bower C.; Yellachich L.; Nguyen H.; Pinder T.; Montgomery P.; Croft M.; Castle D.

Reproductive history in women with serious mental illness
pp. 20-20(1)
Authors: McGrath J.; Barkla J.M.; Jenner L.L.; Plant K.; Hearle J.

Fertility of patients with psychoses versus their unaffected siblings
pp. 20-21(2)
Authors: McGrath J.; Hearle J.; Jenner L.; Plant K.; Drummond A.; Barkla J.

Symptomatology in subjects with non-affective psychosis and substance misuse
pp. 21-21(1)
Authors: Cantwell R.; Brewin J.; Glazebrook C.

Psychosis and cannabis use
pp. 21-21(1)
Authors: Grech A.; Takei N.; Murray R.M.

Prevalence of substance use disorder in an Australian schizophrenia-spectrum multiply-affected family study
pp. 21-22(2)
Authors: Clair A.L.; Mowry B.J.

Comparison of cannabis use in psychotic patients and controls in London and Malta
pp. 22-22(1)
Authors: Grech A.; Takei N.; Murray R.M.

Schizophrenia, alcohol abuse and violent behaviour
pp. 22-22(1)
Authors: Rasanen P.; Tiihonen J.; Isohanni M.; Rantakallio P.; Lehtonen J.; Moring J.

ICD-10 acute and substance-related psychoses: diagnostic stability at 3 years
pp. 22-22(1)
Authors: Singh S.P.; Cantwell R.; Amin S.; Brewin J.; Jones P.; Croudace T.

Treatment of substance abuse in schizophrenia: pilot of an integrated psychological treatment
pp. 23-23(1)
Authors: Kavanagh D.J.; Young R.; Sitharthan T.; Clark D.; Clair A.; Boyce L.; Heffernan E.; Thompson K.

Occurrence of hallucinations in a community sample
pp. 23-23(1)
Authors: Johns L.C.; Nazroo J.Y.; Bebbington P.; Kuipers E.

Neurodevelopment related variables and schizotypal traits associated in a multivariate analysis of a sample of secondary school children
pp. 23-24(2)
Authors: Rosa A.; Fananas L.; Serrano F.; Barrantes N.; Gutierrez B.; Caparros B.; Obiols J.E.

Psychosis and depression as extremes of normal variation
pp. 24-24(1)
Authors: van Os J.; Verdoux H.; Maurice-Tison S.; Gay B.; Salamon R.; Bourgeois M.

Is early adulthood a critical developmental stage for psychosis proneness? A survey of delusional ideation in normal subjects
pp. 24-24(1)
Authors: Verdoux H.; van Os J.; Maurice-Tison S.; Gay B.; Salamon R.; Bourgeois M.

Determinants of age of onset in psychosis
pp. 24-25(2)
Authors: Castle D.J.; Sham P.C.; Murray R.M.

Heterogeneity in schizophrenia: a mixture model analysis based on age-of-onset, gender and diagnosis
pp. 25-25(1)
Authors: McLachlan G.; Welham J.; McGrath J.

Opportunities for early identification and treatment of psychosis in primary care
pp. 25-26(2)
Authors: Clark D.H.; Amin S.; Singh S.; Medley I.; Jones P.; Harrison G.

Prediction of delay between onset of psychotic symptoms and first hospitalisation
pp. 26-26(1)
Authors: Verdoux H.; Bergey C.; Assens F.; Abalan F.; Gonzales B.; Fournet O.; Pauillac P.; Liraud F.; Beaussier J.P.; Gaussares C.; Etchegaray B.; Bourgeois M.

Higher schizophrenia incidence in deprived urban areas: evidence for a mechanism of social deterioration
pp. 26-26(1)
Authors: Driessen G.; Gunther N.; Bak M.; van Sambeek M.; van Os J.

Schizophrenia and city life
pp. 26-27(2)
Author: Freeman H.L.

High rates of psychosis in urban areas: effect of urban birth or residence?
pp. 27-27(1)
Authors: Marcelis M.; van Os J.

Season of birth and schizophrenia: a systematic review and meta-analysis of data from the southern hemisphere
pp. 27-27(1)
Authors: McGrath J.J.; Welham J.

Seasonal influences on admissions in schizophrenia and affective disorder: a comparison of onset and relapse
pp. 27-28(2)
Authors: Clarke M.; Keogh F.; Morris M.; Larkin C.; Walsh D.; O'Callaghan E.

Season of birth in schizophrenia, seasonal fertility and prematurity
pp. 28-28(1)
Authors: Miller R.; Winders K.

The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia
pp. 28-28(1)
Authors: Beasley C.M.; Sayler M.E.; Kiesler G.M.; Potvin J.H.; Sanger T.M.; Tollefson G.D.

The effect of an educational intervention on insight and suicidal ideation in schizophrenia
pp. 28-29(2)
Authors: Carroll A.; Clyde Z.; Fattah S.; Coffey I.; Johnstone E.C.; Owens D.C.

Prediction of suicide in a first episode schizophrenic cohort
pp. 29-29(1)
Authors: White C.J.; Hopkins R.S.; Montague L.; Lewis S.W.

The association between positive symptom ratings and negative symptom ratings differs according to clinical state
pp. 31-31(1)
Authors: Alvir J.M.J.; Woerner M.G.; Lieberman J.A.

Schizophrenic sub-syndromes remain stable while pharmacological treatment improves symptoms
pp. 31-31(1)
Authors: Bender S.; Schall U.; Oades R.D.; Olbrich H.M.; Falkai P.; Hornstein C.; Schone W.

The factor structure for psychotic symptoms in patients with schizophrenia over three clinical states
pp. 31-32(2)
Authors: Lahti A.C.; Chen L.W.; Warfel D.; Corey P.K.; Bartko J.; Tamminga C.A.

A confirmatory factor analytic study of symptom dimensions in schizophrenia
pp. 32-32(1)
Authors: Lam L.C.W.; Chen E.Y.H.; Nguyen D.G.H.; Chen R.Y.L.

Time series models of symptoms in schizophrenia
pp. 32-32(1)
Authors: Tschacher W.; Kupper Z.

Negative symptoms improve in deficit and nondeficit schizophrenia
pp. 32-33(2)
Authors: Tandon R.; Goldman M.; Jibson M.; DeQuardo J.R.; Taylor S.F.; Decker L.

Deficit and negative subtypes in schizophrenia: clinical and biological differences
pp. 33-33(1)
Authors: Dollfus S.; Brazo P.; Nkam I.; Thibaut F.; Moity F.; Langlois S.; Gourrevitch R.; Dassa D.; Denise P.; Levillain D.; Halbecq I.; Delamillieure P.; Van Der Elst A.; Segard L.; Assouly-Besse F.; Vasse T.; Etard O.; Guelfi J.D.; Launay C.; Petitjean F.; Petit M.

Prevalence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders
pp. 33-33(1)
Authors: Cassano G.B.; Pini S.; Mastrocinque T.; Saettoni M.; Papasogli A.; Dell'Osso L.

Insight and symptoms of psychosis: a prospective inpatient study
pp. 34-34(1)
Author: Chen E.Y.H.

Are insight measures related to other symptoms in first episode schizophrenia?
pp. 34-34(1)
Authors: Drake R.J.; Haley C.; Lewis S.W.

Improving insight and compliance: predictions and consequences
pp. 34-35(2)
Authors: David A.S.; Kemp R.; Kirov G.; Everitt B.; Hayward P.

A Bi-hemispheric theory of the origin of schneiderian nuclear symptoms
pp. 35-35(1)
Author: Crow T.J.

Changes in psychopathology in first episode schizophrenia
pp. 35-35(1)
Authors: Drake R.J.; Haley C.; Faragher B.; Lewis S.W.

Frequency of first rank symptoms in white and African-Caribbean psychotic patients
pp. 35-35(1)
Authors: Hutchinson G.; Takei N.; Sham P.; Harvey I.; Murray R.M.

Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia?
pp. 36-36(1)
Authors: Keefe R.S.E.; Courtney M.; Bayan U.J.; Harvey P.D.; McEvoy J.M.

Training and inter-rater reliability using the PANSS: the Australian PANSS reliability extension programme (PREP)
pp. 36-36(1)
Author: Lambert T.J.R.

Duration of untreated psychosis in first episode schizophrenia
pp. 36-37(2)
Authors: Hayley C.; Drake R.J.; Faragher B.; Lewis S.W.

Duration of initially untreated psychosis predicts selectively the &unknown;psychomotor poverty&unknown; factor in schizophrenia
pp. 37-37(1)
Authors: Meagher D.; Quinn J.; Murphy P.; Kinsella A.; Mullaney J.; Waddington J.L.

The psychosis rating scale (PRS): a new scale for positive symptoms of psychosis derived from neurodynamic theory
pp. 37-37(1)
Authors: Miller R.; Chouinard G.

Symptoms of schizophrenia in daily life: I. hallucinations
pp. 37-38(2)
Authors: Delespaul P.A.E.G.; deVries M.W.; Myin-Germeys I.

The relationship between the phenomenology of auditory hallucinations and the perceived efficacy of coping mechanisms
pp. 38-38(1)
Authors: Copolov D.L.; Mackinnon A.J.; Thomas R.; Sims E.F.; Seal M.L.

Symptoms of schizophrenia in daily life: II. delusions
pp. 38-38(1)
Authors: Myin-Germeys I.; Delespaul P.A.E.G.; deVries M.W.

Schizophrenics show delusion-incongruent causal reasoning
pp. 38-39(2)
Authors: Simpson J.; Done D.J.

Symptoms of schizophrenia in daily life: III. flat affect
pp. 39-39(1)
Authors: Myin-Germeys I.; Delespaul P.A.E.G.; de Vries M.W.

Organic brain disturbances and symptomatology in schizophrenic and affective disorders
pp. 39-39(1)
Authors: Salokangas R.K.R.; Ilonen T.; Taiminen T.; Karlsson H.; Lauerma H.; Leinonen K.-M.; Wallenius E.; Ranta K.

The correlates of delusional thinking--preliminary findings using the PDI in the normal population
pp. 39-40(2)
Authors: Peters E.; Day S.; Linney Y.; Medford S.; Sharpley M.; Riley S.; Ward F.

Assessment of psychopathological dimensions improves clinical reasoning
pp. 40-40(1)
Authors: van Os J.; Gilvarry C.; Bale R.; van Horn E.; Tattan T.

Improved methods for case characterisation in neuropathology using the item group checklist (SCAN)
pp. 40-40(1)
Authors: Little C.; Garrick T.; Catts S.V.

The psychosis observational rating system (pors)&unknown;: a progress report
pp. 41-41(1)
Authors: Catts S.V.; Andrews S.; Bird K.; Ward P.B.; Liebert B.J.; Spinks N.; McConaghy N.

Acute polymorphous psychotic disorders: their relationship to schizophrenia
pp. 41-41(1)
Authors: Marneros A.; Pillmann F.; Haring A.

Problem solving ability and clinical correlates in schizophrenia
pp. 43-43(1)
Authors: Bustini M.; Stratta P.; Daneluzzo E.; Casacchia M.; Rossi A.

Evidence for executive dysfunction in young people at high genetic risk for schizophrenia? Results of the hayling sentence completion test
pp. 43-43(1)
Authors: Byrne M.; Hodges A.; Grant E.; Johnstone E.C.

The dysexecutive syndrome and social functioning in schizophrenia
pp. 43-44(2)
Authors: Clarke M.; Thampi A.; Mulholland C.; McCrum B.

The role of executive function for intention formation in schizophrenia
pp. 44-44(1)
Authors: Kondel T.K.; Laws K.R.; McKenna P.J.

Assessment of executive functions in schizophrenia
pp. 44-44(1)
Authors: Krabbendam L.; Derix M.M.A.; Jolles J.

The factor structure of the WCST: differences between schizophrenic patients and controls
pp. 44-45(2)
Authors: Rossell S.L.; David A.S.

Processing of context information in schizophrenia
pp. 45-45(1)
Authors: Stratta P.; Daneluzzo E.; Bustini M.; Casacchia M.; Rossi A.

The performance of a psychomotor planning task in patients with schizophrenia
pp. 45-45(1)
Authors: van Dijke I.; Jogems-Kosterman B.J.M.; van Hoof J.J.M.

Is the central executive intact in schizophrenia in the context of impaired working memory?
pp. 46-46(1)
Authors: Greenwood K.E.; Wykes T.; Sigmundsson T.; Morris R.G.

Memory, consciousness and schizophrenia
pp. 46-46(1)
Authors: Danion J.M.; Rizzo L.

Externally ordered and self-ordering working memory tasks in schizophrenia
pp. 46-46(1)
Authors: Hijman R.; Baare W.F.C.; van Haren N.; Pronk S.; van der Linden J.; Kahn R.S.

Verbal and visual memory deficits in schizophrenia
pp. 47-47(1)
Authors: Hijman R.; Hulshoff Pol H.E.; Gispen-de Wied C.C.; van Oel C.; Cahn W.; van der Linden J.; Kahn R.S.

Incentive improves recall but not recognition memory performance in schizophrenia
pp. 47-47(1)
Authors: Kondel T.K.; Laws K.R.; McKenna P.J.

Errorless learning as a treatment for memory impaired schizophrenic patients
pp. 47-47(1)
Authors: Lawrie S.M.; Russell H.; Johnstone E.C.; O'Carroll R.E.

Access and store memory disorders in schizophrenia reflect deficit severity
pp. 47-48(2)
Authors: Laws K.R.; McKenna P.J.; Kondel T.K.

Working memory in schizophrenia and mania: acute and subacute phases
pp. 48-48(1)
Authors: McGrath J.; Chapple B.; Wright M.

Autobiographical recall in schizophrenia: confabulation or delusional memory?
pp. 48-48(1)
Authors: Nathaniel-James D.A.; Frith C.D.

Spatial working memory impairments in schizophrenic patients with the deficit syndrome
pp. 48-49(2)
Authors: Sigmundsson T.; Greenwood K.E.; Maier M.; Toone B.K.; Ron M.A.; Morris R.G.

Relational learning and memory in patients with schizophrenia
pp. 49-49(1)
Authors: Smith D.; Savage G.; Saling M.; Pantelis C.

Social, medical and psychiatric aspects of schizophrenia in people with pre-morbid cognitive impairment
pp. 49-49(1)
Authors: Doody G.A.; Johnstone E.C.; Sanderson T.L.; Owens D.G.C.

Medical investigations in adolescents with learning disability and schizophrenia compared with other psychiatric diagnoses
pp. 49-50(2)
Author: Scott S.

Cognitive deficits in adolescents with schizophrenia or ADHD
pp. 50-50(1)
Authors: &unknown;ie M.; Rund B.R.; Sundet K.

A comparison of the allen cognitive level test and the wisconsin card sort in adult schizophrenic patients
pp. 50-50(1)
Authors: Secrest L.; Ernst A.; Walisch C.; Tapp A.

Neurocognitive functioning in first episode schizophrenia
pp. 50-51(2)
Authors: Addington J.; Addington D.

Pharmacologic effects on antisaccade abnormalities in first episode and chronic schizophrenia
pp. 51-51(1)
Authors: Patel J.K.M.; Burke J.G.; Reveley M.A.; Morris P.K.

A prospective 2-year follow-up study of cognition in first episode schizophrenic patients
pp. 51-51(1)
Authors: Albus M.; Hubmann W.; Sobizack N.; Mohr F.; Franz U.; Hecht S.; Binder J.

The relationship between neuropsychological and oculomotor deficits in first episode schizophrenia
pp. 52-52(1)
Authors: Hutton S.B.; Crawford T.J.; Duncan L.-J.; Chapman M.; Puri B.K.; Kennard C.; Robbins T.W.; Barnes T.R.E.; Joyce E.M.

Objective and subjective cognitive correlates of psychopathology in first episode patients
pp. 52-52(1)
Authors: Holthausen E.A.E.; Wiersma D.; van den Bosch R.J.

Cognitive and personality characteristics of patients with new schizophrenic and severe affective disorders (SAP-Project)
pp. 52-53(2)
Authors: Ilonen T.; Taiminen T.; Karlsson H.; Lauerma H.; Leinonen K.-M.; Wallenius E.; Ranta K.; Salokangas R.K.R.

Executive function in first episode schizophrenia: improvement at one year
pp. 53-53(1)
Authors: Joyce E.M.; Hutton S.B.; Duncan L.-J.; Chapman M.J.; Puri B.K.; Robbins T.W.; Barnes T.R.E.

Neurological signs predict neuropsychological function in schizophrenia
pp. 53-53(1)
Authors: Arango C.; Buchanan R.W.

Plasma dopamine (DA) activity, DA-D2 binding, neuropsychological signs and conditioned blocking (CB) in schizophrenia
pp. 53-54(2)
Authors: Bender S.; Muller B.; Rao M.L.; Henning U.; Sartory G.; Finkbeiner T.; Oades R.D.

Neuropsychological assessment and vermal cerebellar atrophy in male schizophrenic patients
pp. 54-54(1)
Authors: Bersani G.; Venturi P.; Taddei I.; Tanfani G.; Pancheri P.

Cognitive impairment in deficit and disorganized schizophrenic patients
pp. 54-54(1)
Authors: Brazo P.; Halbecq I.; Segard L.; Langlois-Thery S.; Delamillieure P.; Thibaut F.; Van Der Elst A.; Vasse T.; Petit M.; Dollfus S.

Cognitive and olfactory deficits: course from high risk to first-episode psychosis
pp. 54-55(2)
Authors: Brewer W.; Francey S.; Yung A.; Velakoulis D.; Anderson V.; McGorry P.; Singh B.; Copolov D.; Pantelis C.

Olfactory acuity deficits for the odour of schizophrenia in chronic and first-episode patients
pp. 55-55(1)
Authors: Brewer W.; Velakoulis D.; Anderson V.; Lambert J.; McGorry P.; Singh B.; Copolov D.; Pantelis C.

Neuropsychological assessment of a group of individuals at high genetic risk for schizophrenia and controls
pp. 55-55(1)
Authors: Byrne M.; Hodges A.; Grant E.; Johnstone E.C.

Poor performance of schizophrenic patients on the cognitive bias task
pp. 56-56(1)
Authors: Daneluzzo E.; Stratta P.; Bustini M.; Prosperini P.; Casacchia M.; Rossi A.

Neurocognitive deficits and social functioning in outpatients with schizophrenia: a two year follow-up
pp. 56-56(1)
Authors: Dickerson F.B.; Ringel N.; Parente F.; Boronow J.J.

Schizophrenic dementia: a neuropsychological and imaging study of severe cognitively impaired younger patients
pp. 56-57(2)
Authors: de Vries P.J.; McKenna P.J.

Differentiation of cognitive and motor slowing in the digit symbol test (DST): differences between depression and schizophrenia
pp. 57-57(1)
Authors: van Hoof J.J.M.; Sabbe B.G.C.; Jogems-Kosterman B.J.M.; Zitman F.G.; Hulstijn W.

Convergence of cognitive and adaptive decline in chronic schizophrenia
pp. 57-57(1)
Authors: Harvey P.D.; Parrella M.; White L.; Mohs R.C.; Davis K.L.

Constructional praxis in geriatric schizophrenics
pp. 57-57(1)
Authors: Howanitz E.; Engelhart C.; Eisenstein N.; Harvey P.D.; Lozonczy M.

Figure copying in patients with schizophrenia: relationship between negative symptoms and the complexity of figures
pp. 58-58(1)
Authors: Jogems-Kosterman B.J.M.; Zitman F.G.; van Hoof J.J.M.; Loonen A.J.M.; Hulstijn W.

Comparison of neuropsychological deficits in childhood-onset schizophrenia and multidimensionally impaired syndrome
pp. 58-58(1)
Authors: Kumra S.; Wiggs E.; Bedwell J.; Asarnow R.F.; Rapoport J.L.

A neuropsychological profile of young schizophrenics
pp. 58-59(2)
Authors: Landr&unknown; N.I.

Temporal lobe function and conditional discrimination learning in schizophrenia
pp. 59-59(1)
Authors: Margreiter-Neuwirth N.; Eberstaller M.; Hofer E.; Anderer P.; Neuwirth W.; Semlitsch H.V.; Dantendorfer K.

Cognitive impairment in alzheimers disease and schizophrenia
pp. 59-59(1)
Authors: Marin D.; Harvey P.D.; Mohs R.C.; Davis K.L.

Rorschach &unknown;schizophrenia&unknown; signs in healthy first degree family members of patients with schizophrenia. A study of three complete families
pp. 59-60(2)
Author: Meurice E.E.

Further evidence of a relationship between self-monitoring impairments and positive symptoms in schizophrenia
pp. 60-60(1)
Authors: Ndlovu P.; Stirling J.D.; Hellewell J.S.E.

Motion perception in schizophrenic patients
pp. 60-60(1)
Authors: O'Driscoll G.A.; Florencio P.S.; Grivell J.; Wolff A.L.; Joober R.; Lal S.; Baker C.L.

The New York high-risk project: IQ-scatter as predictor of schizophrenia
pp. 60-61(2)
Authors: Ott S.L.; Rock D.; Erlenmeyer-Kimling L.

Investigation of the cognitive processes underlying paranoia using visual scan paths
pp. 61-61(1)
Authors: Phillips M.L.; Senior C.; David A.S.

Sentence verification and delusions: a content-specific deficit
pp. 61-61(1)
Authors: Rossell S.L.; Shapleske J.; David A.S.

Application of the &unknown;rough set&unknown; model for the evaluation of self-experienced neuropsychological deficits as predictors for schizophrenia. Results of an 8-year follow-up prospective study.
pp. 61-62(2)
Authors: Schultze-Lutter F.; Klosterkotter J.; Steinmeyer E.M.

Are self-experienced neuropsychological deficits able to predict schizophrenia? Results of a prospective follow-up study
pp. 62-62(1)
Authors: Schultze-Lutter F.; Steinmeyer E.M.; Klosterkotter J.

Deficits in source monitoring in subjects with auditory hallucinations may be due to differences in verbal intelligence and verbal memory
pp. 62-62(1)
Authors: Seal M.L.; Crowe S.F.; Cheung P.

Test-retest reliability of the national adult reading test (NART) as an estimate of premorbid IQ in patients with schizophrenia
pp. 62-63(2)
Authors: Smith D.; Roberts S.; Brewer W.; Pantelis C.

Do specific neurocognitive deficits predict specific dimensions of outcome in schizophrenia?
pp. 63-63(1)
Authors: Velligan D.I.; Bow-Thomas C.C.; Mahurin R.K.; Miller A.L.

Conceptualization and attribute rating of emotional facial expressions in schizophrenic patients
pp. 63-63(1)
Authors: Weniger G.; Irle E.; Ruther E.

Schizophrenia impairs synchronous reproduction of rhythmic structures
pp. 64-64(1)
Authors: Levkovitz Y.; Barash S.

Are self-experienced neuropsychological deficits able to indicate a liability to schizophrenia? Results of a comparative study of 1st-degree relatives of schizophrenics
pp. 64-64(1)
Authors: Klosterkotter J.; Schultze-Lutter F.; Steinmeyer E.M.; Wieneke A.

The maudsley early onset schizophrenia study: cognitive deficits in adolescent onset schizophrenia
pp. 64-64(1)
Authors: Kravariti J.; Morris R.; Frangou S.

Deficit in nonverbal communicative abilities of early-psychotic patients during social interaction: therapeutic efficacy of neuroleptic drug treatment
pp. 65-65(1)
Authors: Altorfer A.; Merlo M.C.G.; Kaesermann M.L.; Jossen S.; Hofer H.

Dissecting the components of linguistic processing in schizophrenia using functional MRI
pp. 65-65(1)
Authors: Honey G.D.; Soni W.; Bullmore E.T.; Varatheesan M.; Williams S.C.R.; Andrew C.; Morris R.G.; Sharma T.

Impaired sensitivity to linguistic context online: a state marker of schizophrenic thought disorder?
pp. 65-66(2)
Authors: Kuperberg G.R.; McGuire P.K.; Murray R.M.; David A.S.

Semantic facilitation and interference: behavioural and electrophysiological evidence for a deficit in schizophrenia
pp. 66-66(1)
Authors: Kuperberg G.R.; Murray R.M.; Binnie C.D.; Andrews H.B.

Use of language in pre-schizophrenic children
pp. 66-66(1)
Authors: Leinonen E.; Done D.J.; Crow T.J.

Syntax and semantics in schizophrenic formal thought disorder: a study using the single case approach
pp. 66-67(2)
Authors: Oh T.M.; McCarthy R.A.; McKenna P.J.

Neural correlates of processing British Sign Language (BSL) in the deaf
pp. 67-67(1)
Authors: Robertson D.; Thacker A.; David A.S.; Kitson N.; Frackowiak R.S.J.; Frith C.D.; McGuire P.K.

Semantic memory impairment correlates with thought disorder
pp. 67-67(1)
Authors: Vassallo M.; Crow T.J.; Leinonan E.

Sex-related effects of cerebral asymmetry on cognition: further evidence relating to the genetic predisposition to psychosis
pp. 69-69(1)
Authors: Crow T.J.; Crow L.R.; Done D.J.; Leask S.

Anomalies of anatomical asymmetry detected in first episode cases of schizophrenic illness by a new method of MRI reconstruction and analysis
pp. 69-69(1)
Authors: Crow T.J.; Feldmar J.; Guillemaud R.; Sakuma M.; Zisserman A.; Marais P.; Delisi L.E.; Brady J.M.

fMRI studies of schizophrenia: lateralization and medication effects
pp. 69-70(2)
Authors: Braus D.F.; Ende G.; Sartorius S.; Krier A.; Rossler W.; Martini M.; Henn F.A.

The anatomy of the fornix and schizophrenia: a post mortem study
pp. 70-70(1)
Authors: Chance S.A.; Highley J.R.; Crow T.J.

Cerebral asymmetry and treatment response in schizophrenia
pp. 70-70(1)
Authors: Chapman R.D.; Whalley H.; Rimmington J.E.; Best J.J.K.; Johnstone E.C.; Lawrie S.M.

Evidence of abnormal lateralisation of motor systems in schizophrenia using functional MRI
pp. 70-71(2)
Authors: Honey G.D.; Soni W.; Bullmore E.T.; Varatheesan M.; Williams S.C.R.; Andrew C.; Sharma T.

Superior temporal gyral volumes and laterality correlates of auditory hallucinations in schizophrenia
pp. 71-71(1)
Authors: Levitan C.; Ward P.B.; Catts S.V.

A post mortem study of the size and asymmetry of the parahippocampal and fusiform gyrii in schizophrenia
pp. 71-71(1)
Authors: McDonald B.; Highley J.R.; Walker M.A.; Herron B.; Cooper S.; Crow T.J.

Hippocampal volume in sporadic schizophrenics, multiple affected families with schizophrenia and normal controls. A morphometric MRI study
pp. 71-72(2)
Authors: Tepest R.; Alfter D.; Cordes J.; Schonell H.; Steudel M.; Honer W.G.; Falkai P.

Evidence for hemispheric symmetry in schizophrenia from computer measurements in postmortem tissue of left & right hippocampus
pp. 72-72(1)
Author: Zaidel D.W.

Correlations between age and morphology in left & right hippocampal tissue from schizophrenic & normal subjects
pp. 72-72(1)
Author: Zaidel D.W.

Why the hippocampus in schizophrenia? A theoretical consideration of the function of memory in normal people and in schizophrenic patients
pp. 72-72(1)
Author: Zaidel D.W.

Violence and psychosis: an MRI and MRS study of medial temporal lobe asymmetry in violent people with and without a psychotic illness
pp. 73-73(1)
Authors: Van Amelsvoort T.; Critchley H.; Robertson D.; Simmons A.; Xenitidis K.; Russell A.; Henry J.; Murphy D.G.M.

Abnormal lateral ventricular asymmetry in schizophrenia
pp. 73-73(1)
Authors: Kawasaki Y.; Mizukoshi C.; Nagasawa T.; Higashima M.; Maeda Y.; Koshino Y.

Lateralized olfactory acuity deficits and olfactory misidentification in schizophrenia
pp. 73-73(1)
Authors: Purdon S.E.; Pasmeny G.; Doerkson S.; Waldie B.

Abnormal lateralization of certain event-related potential (ERP) indices is present after but not during an acute exacerbation of schizophrenia
pp. 74-74(1)
Authors: Wolstein J.; Schall U.; Bender S.; Butorac M.; Muller B.; Hagen S.; Zerbin D.; Oades R.D.

Time sharing: the answer to too much symmetry
pp. 74-74(1)
Author: Thomas J.

Structural imaging in subjects at high risk for schizophrenia
pp. 75-75(1)
Authors: Lawrie S.M.; Whalley H.; Hodges A.; Abukmeil S.; Best J.J.K.; Johnstone E.C.

Cerebral volumetric changes in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study
pp. 75-75(1)
Authors: Bachmann S.; Weimer D.; Schroder J.; Essig M.; Baudendistal K.; Pantel J.; Herre H.; Muller C.; Schad L.R.; Knopp M.V.; Resch F.; Mundt C.

A CT study of ventricular size in first episode psychosis
pp. 75-75(1)
Authors: Danckert J.; Velakoulis D.; McGorry P.; Bridle N.; Kelman A.; Hoberton A.; Pantelis C.

A longitudinal MRI study of first-episode schizophrenia: assessment of cerebral changes and quantitation of ventricular changes
pp. 76-76(1)
Authors: Puri B.K.; Saeed N.; Oatridge A.; Hajnal J.V.; Hutton S.B.; Duncan L.-J.; Chapman M.J.; Barnes T.R.E.; Bydder G.M.; Joyce E.M.

The progression of brain structural changes in schizophrenia: update on clinical/cognitive significance and its underlying basis
pp. 76-76(1)
Authors: DeLisi L.E.; Ge S.; Sakuma M.; Grimson R.; Kushner M.; Hoff A.L.

Typology of schizophrenia: static vs atrophic brain psychoses; premorbidity, symptoms, and neuroleptic effects
pp. 76-77(2)
Authors: Garver D.L.; Nair T.R.; Christensen J.D.; Holcomb J.; Kingsbury S.J.

MRI volumetric follow-up study of schizophrenic patients
pp. 77-77(1)
Authors: Honeder M.; Whitworth A.B.; Kemmler G.; Kremser C.; Felber S.; Wechdorn H.; Hausmann A.; Wanko C.; Stuppack C.H.; Fleischhacker W.W.

Landmark-based shape analysis of deficit versus non-deficit schizophrenia
pp. 77-77(1)
Authors: DeQuardo J.R.; Buchanan R.W.; Kirkpatrick B.; Bookstein F.L.; Tandon R.

The maudsley early onset schizophrenia study: brain structural abnormalities in adolescent onset schizophrenia
pp. 77-78(2)
Authors: Frangou S.; Kravariti J.; Simmons A.; Andrews C.; Williams S.; Pipe R.; Murray R.

MRI study of adolescent onset (DSM-III-R) schizophrenia
pp. 78-78(1)
Authors: James A.; Wardell M.; Renowden S.; Anslow P.

MRI morphometrics and volumetric analyses of cerebral morphology in schizophrenia
pp. 78-78(1)
Authors: Buckley P.F.; Dean D.; Bookstein F.L.; Friedman L.; Kwon D.; Lewin J.S.; Kamath J.; Lys C.

Meta-anlayses of the studies relating psychopathology and structural brain abnomarlities in schizophrenia
pp. 78-79(2)
Authors: Kimura L.H.; Nita L.M.; Eizenman B.; Elkis H.

Smaller corpus callosum brain ratio (CCBR) and absence of correlation with linear measure of corpus callosum (CC) in schizophrenic patients: a magnetic resonance imaging (MRI) study
pp. 79-79(1)
Authors: Bersani G.; Iannitelli A.; Zucca C.; Silvestrini C.; Cipriano P.; Gualdi G.F.; Pancheri P.

Are the corpus callosum abnormalities seen in schizophrenia related to pregnancy & birth complications?
pp. 79-79(1)
Authors: Fearon P.; Aquino P.; O'Connell P.; Frangou S.; Taylor M.; Lewis S.; Murray R.M.; Rifkin L.

Further evidence that ventricular enlargement may be mediated by pregnancy and birth complications in schizophrenia
pp. 79-80(2)
Authors: Fearon P.; O'Connell P.; Frangou S.; Taylor M.; Lewis S.; Murray R.M.; Rifkin L.

Use of magnetization transfer imaging in vivo to investigate the neuropathology in schizophrenia
pp. 80-80(1)
Authors: Foong J.; Maier M.; Barker G.; Miller D.H.; Ron M.A.

Caudate volume changes across three stages of psychosis
pp. 80-80(1)
Authors: Velakoulis D.; Pantelis C.; McGorry P.; Yung A.; Brewer W.J.; Bridle N.; Tierney P.; Le T.; Desmond P.M.; Singh B.; Copolov D.

First line clozapine effect on basal ganglia volumes
pp. 80-81(2)
Authors: Gunduz H.; Wu H.; Ashtari M.; Bogerts B.; Robinson D.; Becker J.; Bilder R.

Brain morphology in schizophrenia and substance use
pp. 81-81(1)
Authors: Scheller-Gilkey G.; Lewine R.R.J.; Caudle J.

Both schizophrenic and bipolar adolescents differ from controls on MRI measures
pp. 81-81(1)
Authors: Schulz S.C.; Friedman L.; Findling R.; Kenny J.; Swales T.; Wise A.

Area and volume measurements of the planum temporale in schizophrenia using structural MRI
pp. 81-82(2)
Authors: Shapleske J.; Rossell S.L.; David A.S.; Woodruff P.W.R.

Clinical and structural abnormalities in schizophrenia
pp. 82-82(1)
Authors: Shenton M.E.; Hirayasu Y.; Salisbury D.F.; Dickey C.C.; Kwon J.S.; Niznikiewicz M.M.; Wible C.G.; Nester P.G.; McCarley R.W.

Brain morphology as a predictor of outcome in schizophrenia
pp. 82-82(1)
Authors: Wassink T.H.; Nopoulos P.; Flaum M.; Andreasen N.C.

Hippocampal abnormalities in schizophrenia: findings from neurotransmitter and structural imaging studies
pp. 82-83(2)
Authors: Copolov D.L.; Dean B.; Velakoulis D.; Naylor L.; Opeskin K.; Pavey G.; Hill C.; Keks N.; Yung A.; McGorry P.; Seal M.L.; Pantelis C.

The site of hippocampal volume reduction differs between first-episode and chronic schizophrenia
pp. 83-83(1)
Authors: Velakoulis D.; Pantelis C.; Stuart G.; McGorry P.; Yung A.; Brewer W.J.; Bridle N.; Desmond P.M.; Singh B.; Copolov D.

No increase in abnormalities in the clinical neuroradiological exam in schizophrenia
pp. 83-83(1)
Authors: Hulshoff Pol H.E.; Gispen-de Wied C.C.; Ramos L.M.; Van der Linden J.; Cahn W.; Selten J.P.; Van Oel C.; Baare W.F.C.; Staal W.G.; Mali W.P.T.M.; Kahn R.S.

Laplacian brainprint--a MRI based method for the 2D representation of the sulcal pattern
pp. 83-84(2)
Authors: Haidekker M.A.; Evertsz C.J.G.; Boor S.; Stoeter P.; Fitzek C.; Peitgen H.O.

Post-mortem brain weight in schizophrenia and affective disorder
pp. 85-85(1)
Authors: Bigelow L.B.; Torrey E.F.

Alteration of thalamocortical circuitry in schizophrenia
pp. 85-85(1)
Authors: Danos P.; Baumann B.; Bernstein H.G.; Northoff G.; Stauch R.; Bogerts B.

An investigation into the synaptic pathology of schizophrenia
pp. 85-86(2)
Authors: Eva R.; Stevan J.; Royston M.C.

Abnormal synaptic connectivity in schizophrenia
pp. 86-86(1)
Authors: Stefan M.D.; Falkai P.; Bullmore E.T.; Royston M.C.

Increased numerical density of synapses in layer VI of postmortem prefrontal cortex in schizophrenia
pp. 86-86(1)
Authors: Uranova N.A.; Vikhreva O.V.; Orlovskaya D.D.; Denisov D.V.

Increase in microglia in frontal and temporal cortex of schizophrenics
pp. 86-87(2)
Authors: Radewicz K.; Garey L.J.; Reynolds R.

A validation of MRI cortical surface rendering of the human post-mortem brain
pp. 87-87(1)
Authors: Chance S.A.; McDonald B.; Gerig G.; Highley J.R.; Crow T.J.

Disturbed gyrification and reduced volume of the prefrontal lobe in male schizophrenics--a morphometric postmortem study
pp. 87-87(1)
Authors: Vogeley K.; Schneider-Axmann T.; Tepest R.; Pfeiffer U.; Bogerts B.; Honer W.G.; Falkai P.

Specific increase in size of lamina II pyramidal cells in the entorhinal cortex in schizophrenia
pp. 87-88(2)
Authors: Longson D.; Longson C.M.; Deakin J.F.W.; Benes F.M.

A stereological study of the volume of the hippocampus in post mortem control and schizophrenic brains
pp. 88-88(1)
Authors: Walker M.A.; Highley J.R.; McDonald B.; Roberts H.; Crow T.J.

Synaptic pathology in schizophrenia: differential involvement of the complexins
pp. 88-88(1)
Authors: Harrison P.J.; Eastwood S.L.

Spinophilin: alterations in a post-synaptic marker in schizophrenia
pp. 88-89(2)
Authors: De I.; Allen P.; Ross C.A.; Yolken R.H.; Torrey E.F.

Calretinin-expressing neurones in the hippocampus of schizophrenics
pp. 89-89(1)
Authors: Bayer T.A.; Vogeley K.; Bogerts B.; Honer B.; Falkai P.

Specificity of GABAergic deficits in the frontal cortex in schizophrenia
pp. 89-89(1)
Authors: Beasley C.L.; Reynolds G.P.

Increased hippocampal dendritic expression of non-phosphorylated MAP2 protein in schizophrenia
pp. 89-90(2)
Authors: Cotter D.; Roberts E.; Kerwin R.; Doshi B.; Everall I.

Alterations in the cytoplasmic state of neuronal beta and gamma catenin in the hippocampus in schizophrenia
pp. 90-90(1)
Authors: Cotter D.; Kerwin R.; Al-Sarraj S.; Doshi B.; Lovestone S.; Anderton B.; Everall I.

The role of catenins and adenomatous polyposis coli (APC) in neurodevelopment: abnormalities in focal cortical dysplasia
pp. 90-90(1)
Authors: Everall I.P.; Cotter D.C.; Honavar M.; Anderton B.; Kerwin R.W.

Identification of differentially expressed messages in the hippocampi and frontal cortices of mentally ill individuals
pp. 90-91(2)
Authors: Johnston N.L.; Leister F.; Li S.; Yolken R.H.; Torrey E.F.

Identification of abnormal protein levels in the frontal cortices of brains from mentally ill individuals by two-dimensional gel electrophoresis
pp. 91-91(1)
Authors: Johnston N.L.; Shore A.D.; Yolken R.H.; Torrey E.F.

An automated position analysis of parvalbumin-immunoreactive cells in the cerebral cortex in control and schizophrenic post-mortem brain
pp. 91-91(1)
Authors: Leclercq P.D.; Garey L.J.; Gentleman S.M.; McKenzie J.E.; Hirsch S.R.; Royston M.C.

Increased CSF and brain quinolinic acid in schizophrenia and bipolar disorder
pp. 91-92(2)
Authors: Torrey E.F.; Yolken R.H.; Zito M.; Heyes M.

Screening for viral nucleic acid sequences in CSF and brain tissue obtained postmortem from individuals with schizophrenia or bipolar disease
pp. 92-92(1)
Authors: Karlsson H.; Leister F.; Johnston N.L.; Yolken R.H.

Differential expression of viral and virus-associated RNA transcripts in the brains of individuals with schizophrenia and bipolar disorder
pp. 92-92(1)
Authors: Yee F.; Johnston N.L.; Leister F.; Li S.; Ross C.A.; Torrey E.F.; Yolken R.H.

Dopamine D₄ receptors in human postmortem brain tissue of normal and schizophrenic subjects. An [³]NGD-94-1 study
pp. 93-93(1)
Authors: Lahti R.A.; Roberts R.C.; Cochrane E.V.; Primus R.J.; Gallager D.W.; Tamminga C.A.

Which dopamine receptor mediates psychosis: the horns of a dilemma
pp. 93-93(1)
Author: Miller R.

Increased synthesis of dopamine in prefrontal cortex and striatum in drug-naive schizophrenic patients studied by use of C¹¹-labelled I-DOPA and positron emission tomography (PET)
pp. 93-94(2)
Authors: Lindstrom L.H.; Gefvert O.; Hagberg G.; Hagstrom P.; Lundberg T.; Bergstrom M.; Hartvig P.; Langstrom B.

[¹¹C]raclopride pet detects dopamine release induced by behavioural manipulation
pp. 94-94(1)
Authors: Grasby P.M.; Koepp M.J.; Gunn R.N.; Cunningham V.J.; Lawrence A.; Bench C.J.

Prefrontal cortical control of subcortical dopamine transmission
pp. 94-94(1)
Author: Svensson T.H.

Dissociative effects of MK-801 on mesocortical and mesolimbic dopamine neurons
pp. 94-95(2)
Authors: Svensson T.H.; Mathe J.M.; Nomikos G.G.; Blakeman K.H.

Plasma indicators of monoamine metabolism and nicotine consumption: a factor and correlational analysis with schizophrenic symptom clusters
pp. 95-95(1)
Authors: Rodewald S.; Muller B.; Oades R.D.; Henning U.; Rao M.L.; Bender S.; Wolstein J.

Brain 5-Hydroxytryptamine function in treatment resistant schizophrenia
pp. 95-95(1)
Authors: Golightly K.L.; Young A.H.

5-HT stimulation increases basal ganglia dopamine release in human model psychosis: a pet study with [11C]raclopride
pp. 96-96(1)
Authors: Vollenweider F.X.; Vontobel P.; Leenders K.L.; Hell D.

Regional specificity of changes in the expression of NMDA receptor and cholecystokinin mRNA in schizophrenia
pp. 96-96(1)
Authors: de Belleroche J.; Humphries C.; Durnin A.; Mortimer A.; Hirsch S.

The role of glutmate and HVA in schizophrenic symptomatology
pp. 96-97(2)
Authors: van Kammen D.P.; Kelley M.E.; Yao J.K.; Tsai G.; Coyle J.T.

GABA_A receptors are not altered in the auditory-linguistic association cortex of subjects with schizophrenia but are markedly decreased in the auditory cortex of rats treated with clozapine and olanzapine
pp. 97-97(1)
Authors: Farnbach-Pralong D.; Bradbury R.; Copolov D.L.; Dean B.

Defining and modelling the frontal cortical neuronal deficits in schizophrenia
pp. 97-97(1)
Authors: Reynolds G.P.; Beasley C.L.; Aparicio-Legarza M.I.; Quint E.

Differential anatomical localization of dopamine and ionotropic glutamate receptor subtypes in caudate-putamen
pp. 98-98(1)
Authors: Tarazi F.I.; Campbell A.; Yeghiayan S.K.; Baldessarini R.J.

Is schizophrenia an autoimmune disease?
pp. 98-98(1)
Authors: Rothermundt M.; Arolt V.; Weitzsch C.; Kirchner H.

The alteration of lymphocyte functional activity in patients with mental disorders
pp. 98-99(2)
Authors: Sekirina T.P.; Androsova L.V.; Kolyaskina G.I.; Kaleda V.G.

The number and cytotoxic activity of natural killer cells in schizophrenia and effective disorders
pp. 99-99(1)
Authors: Vasiliyeva E.F.; Kolyaskina G.I.; Kushner S.G.; Tsutsulkovskaya M.Y.

Leucocyte glycolysis in schizophrenic patients
pp. 99-99(1)
Author: Zhankov A.I.

Meta-analysis of P³¹ MR spectroscopy studies in schizophrenia
pp. 99-100(2)
Authors: Buckley P.F.; Friedman L.; Dasari M.; Schulz S.C.

Proton magnetic resonance spectroscopy and schizophrenia
pp. 100-100(1)
Authors: Delamillieure P.; Constans J.M.; Fernandez J.; Brazo P.; Vasse T.; Courtheoux P.; Petit M.; Dollfus S.

The neurobiology of severe and repetetive violence: a ¹HMRS study of frontal lobe
pp. 100-100(1)
Authors: Robertson D.; Critchley H.; Daly E.; Van Amelsvoort T.; Xenitidis K.; Murphy D.

Proton magnetic resonance spectroscopy (¹H-MRS) of putamen in schizophrenic patients with and without tardive dyskinesia
pp. 100-101(2)
Authors: Sigmundsson T.; Wilson H.; Chaudhuri K.R.; Williams S.C.R.; Simmons A.; Leigh P.N.; Toone B.K.

31-Phosphorous-spectroscopy in schizophrenia-further data on medication effects and the relation of findings to psychopatholocy and neuropsychology
pp. 101-101(1)
Authors: Volz H.P.; Rzanny R.; Hubner G.; Roessger G.; Kaiser W.A.; Sauer H.

Medial prefrontal ¹H MRS and MRI findings in never-treated schizophrenics and healthy controls
pp. 101-101(1)
Authors: Williamson P.C.; Bartha R.; Drost D.J.; Malla A.; Carr T.; Canaran G.; Densmore M.; Neufeld R.W.J.

N-CAM abnormalities in schizophrenia
pp. 101-102(2)
Authors: Freed W.J.; Vawter M.

The membrane hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia
pp. 102-102(1)
Author: Horrobin D.F.

Anandamide induces chemiluminescence activating cyclooxygenase in human platelets and may have a role in schizophrenia
pp. 102-102(1)
Authors: Das I.; Kidane L.; Hirsch S.R.

Abnormalities in neurotensin gene expression levels in the hippocampus of schizophrenics
pp. 102-103(2)
Authors: Hamid E.H.; Hyde T.M.; Egan M.F.; Bachus S.E.; Kinkead B.L.; Nemeroff C.B.; Wolf S.S.; Herman M.M.; Kleinman J.E.

Effects of blood serum high and low molecular weight fractions of normal control, untreated and treated schizophrenics on the ultrastructure of nervous tissue culture of human embryos
pp. 103-103(1)
Authors: Uranova N.A.; Orlovskaya D.D.; Buravlev V.M.; Zimina I.S.; Brusov O.S.; Serebryakova M.V.

CSF ace correlates with duration of illness in schizophrenia
pp. 103-103(1)
Authors: Wahlbeck K.; Rimon R.

Glutathione peroxidase (GSHPx) activity in plasma and fibroblasts from schizophrenics and control
pp. 103-104(2)
Authors: Zhang Z.J.; Ramchand C.N.; Ramchand R.; Milner E.; Telang S.D.; Peet M.

A Positron emission tomography (PET) study of verbal fluency in well controlled schizophrenia and bipolar disorder
pp. 105-105(1)
Authors: Dye S.M.; Spence S.A.; Bench C.J.; Grasby P.M.; Hirsch S.R.

An FMRI study of sentence completion in patients with formal thought disorder
pp. 105-105(1)
Authors: Kircher T.; Andrew C.; Murray R.; McGuire P.

Functional neuroanatomical dissociation of verbal, visual and spatial working memory
pp. 105-106(2)
Authors: Murphy D.G.M.; Daly E.M.; Van Amelsvoort T.; Robertson D.; Simmons A.; Critchley H.D.

A PET study of word generation in obligate carriers of the predisposition to schizophrenia
pp. 106-106(1)
Authors: Spence S.A.; Sharma T.; Hellewell J.; Stefan M.; Deakin B.; Murray R.M.; Frith C.D.; Liddle P.F.; Grasby P.M.

Assessment of prefrontal activation by infrequent visual targets and non-target novel stimuli in schizophrenia: a functional MRI study
pp. 106-106(1)
Authors: Belger A.; Kirino E.; McCarthy G.; Gore J.C.; Krystal J.H.

Attenuated frontal activation in schizophrenia--a comparison of two semantic tasks
pp. 107-107(1)
Authors: Curtis V.A.; Bullmore E.T.; Brammer M.J.; Williams S.C.R.; Morris R.G.; Sharma T.S.; Murray R.M.; McGuire P.K.

A functional neuroimaging study of patterns of frontal lobe activity in schizophrenia during memory encoding and retrieval
pp. 107-107(1)
Authors: Fletcher P.C.; McKenna P.J.; Friston K.J.; Dolan R.J.

Prefrontal involvement in schizophrenia
pp. 107-108(2)
Authors: Quak J.; Paans A.M.J.; van den Bosch R.J.; Korf J.

Abnormal frontal ERPs during verbal fluency in schizophrenia
pp. 108-108(1)
Authors: Robins N.M.; Chen C.A.N.; Soni S.D.; Deakin J.F.W.

Mesial frontal underactivation in schizophrenia during inhibitory motor control using functional magnetic resonance imaging (fMRI)
pp. 108-108(1)
Authors: Rubia K.; Russel T.; Taylor E.; Bullmore E.; Brammer M.; Williams S.; Simmons A.; Andrew C.; Sharma T.

Lateral prefrontal cortical activity during spatial memory in schizophrenia: a positron emission tomography (PET) study
pp. 108-109(2)
Authors: Seaward J.R.; Dye S.M.; Bagary M.; Grasby P.M.

Hypofrontality remits with schizophrenic recovery
pp. 109-109(1)
Authors: Spence S.A.; Hirsch S.R.; Brooks D.J.; Grasby P.M.

Decreased frontal activation of schizophrenics during stimulation with the continuous performance test--a functional magnetic resonance imaging study
pp. 109-109(1)
Authors: Volz H.P.; Gaser C.; Hager F.; Rzanny R.; Ponisch J.; Mentzel H.J.; Kaiser W.A.; Sauer H.

Temporal cortical response to speech is less in clozapine-treated than flupenthixol-treated schizophrenic patients
pp. 109-110(2)
Authors: Woodruff P.W.R.; Ha Y.; Wright I.C.; Shapleske J.; Rossell S.; Howard R.; Bullmore E.T.; Brammer M.; Williams S.C.R.; Murray R.M.; David A.S.

Brain activation during cognitive stimulation with the wisconsin card sorting test--a functional MRI study on healthy volunteers and schizophrenics
pp. 110-110(1)
Authors: Volz H.P.; Gaser C.; Hager F.; Rzanny R.; Mentzel H.J.; Kaiser W.A.; Sauer H.

Cortico-striatal and limbic activity during processing of human facial emotions: relevance to schizophrenia
pp. 110-110(1)
Authors: Critchley H.D.; Daly E.M.; Phillips M.; Robertson D.; Van Amelsvoort T.; Brammer M.; Williams S.; Murphy D.G.M.

Discriminating functional connectivity in schizophrenia from normal connectivity using a neural network
pp. 111-111(1)
Authors: Liddle P.F.; Josin G.; Mendrek A.

Distinct neural correlates of &unknown;positive&unknown; and &unknown;negative&unknown; thought disorder
pp. 111-111(1)
Authors: McGuire P.K.; Quested D.; Spence S.; Murray R.; Frith C.; Liddle P.

The Maudsley early onset schizophrenia study: brain in maturational abnormalities in adolescent onset schizophrenia
pp. 111-111(1)
Authors: Frangou S.; Simmons A.; Andrews C.; Clover A.; Williams S.; Pipe R.; Murray R.

Investigation of the neural correlates of threat perception in paranoid schizophrenia: an FMRI study
pp. 112-112(1)
Authors: Phillips M.L.; Senior C.; Bullmore E.T.; Brammer M.; Andrew C.; Williams S.C.R.; David A.S.

Motion-corrected 3D fMRI assessment of visual cortex: schizophrenic patients show the same regional response to photic stimulation as controls
pp. 112-112(1)
Authors: Ramsey N.F.; Jansma J.M.J.; Cahn W.; Mali W.P.T.M.; Kahn R.S.

Brain activation in schizophrenia during performing a go-no-go task in functional magnetic resonance imaging (fMRI)
pp. 112-113(2)
Authors: Rubia K.; Russel T.; Taylor E.; Bullmore E.; Brammer M.; Williams S.; Simmons A.; Andrew C.; Sharma T.

Auditory verbal imagery in differing form
pp. 113-113(1)
Authors: Shergill S.S.; Murray R.M.; McGuire P.K.

Dopamine D4-like receptors in untreated schizophrenic patients demonstrated with PET and ¹¹C-SDZ GLC 756
pp. 113-113(1)
Authors: Klimke A.; Boy C.; Eickhoff M.; Herzog H.; Holschbach M.; Muhlensiepen H.; Weckesser M.; Kops E.R.; Sonnenberg F.; Gaebel W.; Markstein R.; Stocklin G.; Coenen H.H.; Muller-Gartner H.W.

Schizophrenic patients exhibit increased sensorimotor cortex activation with equal performance level
pp. 114-114(1)
Authors: Jansma J.M.; Ramsey N.F.; van der Linden J.A.; Kahn R.S.

Risperidone improves antisaccade error rates in schizophrenia
pp. 115-115(1)
Authors: Burke J.G.; Patel J.K.M.; Morris P.K.; Reveley M.A.

Saccadic and attentional abnormalities in patients with schizophrenia
pp. 115-115(1)
Authors: Danckert J.; Maruff P.; Pantelis C.; Currie J.

Oculomotor abnormalities in first episode schizophrenic patients: a follow-up study
pp. 115-116(2)
Authors: Hutton S.B.; Crawford T.J.; Duncan L.-J.; Chapman M.; Puri B.K.; Kennard C.; Barnes T.R.E.; Joyce E.M.

Smooth pursuit performance over a structured background in first episode schizophrenic patients and controls
pp. 116-116(1)
Authors: Hutton S.B.; Crawford T.J.; Duncan L.-J.; Chapman M.; Puri B.K.; Kennard C.; Barnes T.R.E.; Joyce E.M.

Eye tracking dysfunction (ETD) as a measurable indicator for the vulnerability to schizophrenia
pp. 116-116(1)
Authors: Lencer R.; Nolte A.; Krecker K.; Schwinger E.; Arolt V.

Saccadic eye movements and Wisconsin card sorting test in deficit and nondeficit schizophrenia
pp. 117-117(1)
Authors: Nkam I.; Thibaut F.; Denise P.; Levillain D.; Segard L.; Langlois-Thery S.; Van Der Elst A.; Brazo P.; Delamilleure P.; Vasse T.; Etard O.; Dollfus S.; Petit M.

Antisaccade and no-saccade distractibility with chlorpromazine and lorazepam
pp. 117-117(1)
Authors: Green J.F.; King D.J.

Validation of the clinical antisaccade task to assess distractibility across three stages of psychosis
pp. 117-118(2)
Authors: Velakoulis D.; Danckert J.; Brewer W.; McGorry P.; Yung A.; Maruff P.; Currie J.; Pantelis C.

Deficient memory encoding in the superior temporal gyrus of schizophrenic subjects
pp. 118-118(1)
Authors: Baldeweg T.; Klugman A.; Gruzelier J.; Hirsch S.R.

Auditory event-related brain potentials in healthy volunteers and postacute schizophrenic patients
pp. 118-118(1)
Author: Eichert V.

Event-related desynchronisation in healthy volunteers and postacute schizophrenic patients
pp. 118-119(2)
Author: Eichert V.

Gamma band EEG oscillations in a subject with somatic pseudo-hallucinations
pp. 119-119(1)
Authors: Baldeweg T.; Spence S.; Haenschel C.; Hirsch S.R.; Gruzelier J.

The post-imperative negative variation (PINV) of schizophrenic patients is sensitive to the stressing of working memory functions and the execution of a motor response
pp. 119-119(1)
Authors: Klein C.; Cohen R.; Rockstroh B.; Berg P.

Topography of the PINV in schizophrenia and schizotypy
pp. 119-120(2)
Authors: Klein C.; Rockstroh B.; Berg P.; Elbert T.; Andresen B.

Schizophrenic patients do not spend enough time in one specific brain state: evidence from brain-electric field analysis
pp. 120-120(1)
Authors: Koenig T.; Koukkou M.; Kochi K.; Lehmann D.

An EEG approach to the neurodevelopmental hypothesis of schizophrenia
pp. 120-120(1)
Authors: Koukkou M.; Federspiel A.; Merlo M.C.

Prepulse inhibition (PPI) of event-related potentials (ERPs) in an auditory discrimination is impaired in normal subjects after amphetamine: support for a model of schizophrenia
pp. 120-121(2)
Authors: Kroner S.; Schall U.; Catts S.V.; Ward P.B.

Sensory gating in deficit and non deficit schizophrenics
pp. 121-121(1)
Authors: Louchart S.; Thibaut F.; Van der Elst A.; Dolffus S.; Levillain D.; Petit M.

Localization of hypo- and hyperactivity in neuroleptic-naive, first-break, acute, productive schizophrenia using low resolution electromagnetic tomography (LORETA) registered to the talairach human brain atlas
pp. 121-121(1)
Authors: Pascual-Marqui R.D.; Koukkou M.; Koenig T.; Kochi K.; Lehmann D.

Electrocortical and performance correlates of proactive interference in schizophrenics and controls
pp. 121-122(2)
Authors: Rossner P.; Rockstroh B.; Cohen R.; Wagner M.

Topographic differences of the postimperative negative variation between schizophrenics and controls
pp. 122-122(1)
Authors: Rockstroh B.; Cohen B.J.; Horvath C.; Dobel T.F.

Prepulse inhibition (PPI) of event-related potentials (ERPs) in an auditory discrimination in schizophrenic patients on admission and at discharge
pp. 122-122(1)
Authors: Schall U.; Bender S.; Wolstein J.; Grzella I.; Martens R.; Zerbin D.; Oades R.D.

Construct validation of auditory event-related potential indices of frontal and temporo-parietal information processing in schizophrenia syndromes
pp. 123-123(1)
Authors: Schall U.; Karayanidis F.; Ward P.B.

Event related potentials during a go/no go task in schizophrenia
pp. 123-123(1)
Authors: Smith A.M.; Kiehl K.A.; Liddle P.F.

Polysomnographic abnormalities in schizophrenia: a replication
pp. 123-124(2)
Authors: Tandon R.; Maixner S.; Eiser A.; Shipley J.E.; Taylor S.F.; DeQuardo J.R.

Use of ancillary tests in the differential diagnosis of psychotic psychiatric inpatients
pp. 124-124(1)
Authors: Weiser M.; Hendler T.; Lapidus R.; Prohovnik I.; Abramovitch Y.; Davidson M.

Neuropathological correlates of auditory event-related potentials in recent-onset schizophrenia
pp. 124-124(1)
Authors: Umbricht D.; Bilder R.; Wu H.; Javitt D.; Kane J.

Reduced mismatch reaction in male schizophrenics revealed by means of magnetoencephalography (MEG)
pp. 124-125(2)
Authors: Sauer H.; Rosburg T.; Kreitschmann-Andermahr I.; Meier T.; Volz H.P.; Nowak H.

Myographic characteristics of peripheral nerves of patients with paranoid schizophrenia
pp. 125-125(1)
Authors: Zhankova V.I.; Zhankov A.I.; Logvinovich G.V.; Titarenko V.A.

A polymorphism in the promoter region of the dopamine D2 receptor gene (DRD2) and drug response: association studies
pp. 127-127(1)
Authors: Arranz M.J.; Munro J.; Li T.; Collier D.A.; Kirov G.; Kerwin R.W.

Further evidence for association between polymorphisms in the 5-HT2A receptor gene and clozapine response
pp. 127-127(1)
Authors: Arranz M.J.; Munro J.; Collier D.A.; Krov G.; Sham P.; Zhao J.; Kerwin R.W.

Genetic variation in the 5-HT3 receptor gene: no association with schizophrenia or drug response
pp. 127-128(2)
Authors: Arranz M.J.; Munro J.; Collier D.A.; Kirov G.; Kerwin R.W.

Serotonin transporter gene polymorphism and schizophrenia: an association study
pp. 128-128(1)
Authors: Bonnet-Brilhault F.; Laurent C.; Thibaut F.; Campion D.; Martinez M.; Petit M.; Mallet J.

Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia
pp. 128-128(1)
Authors: Lee K.H.; Ramchand C.N.; Wei J.; Telang S.D.; Vankar G.K.; Shah S.; Peet M.

Genetic differences in phospholipase A2 in control and schizophrenic population
pp. 128-129(2)
Authors: Ramchand C.N.; Wei J.; Lee K.H.; Telang S.D.; Parekh L.J.; Peet M.

A rare allele of a tetranucleotide polymorphic microsatellite, located in the first intron of the tyrosine hydroxylase gene, is associated with schizophrenia and shows transcription regulatory activity in vitro
pp. 129-129(1)
Authors: Meloni R.; Albanese V.; Ravassard P.; Treilhou F.; Mallet J.

Are behavioral syndromes of schizophrenia associated with allelic variations of the tyrosine hydroxylase gene?
pp. 129-129(1)
Authors: Wei J.; Hemmings G.P.

Possible linkage disequilibrium between polymorphic loci for monoamine oxidases A and B in schizophrenia
pp. 129-130(2)
Authors: Wei J.; Ramchand C.N.; Hemmings G.P.

Replication of suggestive evidence linking the 7-nicotinic cholinergic receptor gene on chromosome 15q13-q14 to schizophrenia in Bantu and Malay families
pp. 130-130(1)
Authors: Riley B.P.; Mogudi-Carter M.; Razali M.S.; Sidek M.R.; Isa M.N.; Jenkins T.J.; Williamson R.; Collier D.A.; Murray R.M.

The NMDAR1 receptor gene and schizophrenia
pp. 130-130(1)
Authors: Bolonna A.A.; Makoff A.J.; Collier D.A.; Arranz M.J.; Kerwin R.W.

A second novel polymorphism in the promotor region of the N-acetyltransferase gene (AA-NAT) is not associated with schizophrenia or bipolar affective disorder
pp. 130-131(2)
Authors: Birkett J.T.P.; Collier D.A.; Kerwin R.W.

Delineating A 22q11 deletion subtype of schizophrenia
pp. 131-131(1)
Authors: Scutt L.; Correia S.; Chow E.; Hogan J.; Hodgkinson K.; Jones C.; Honer W.; Kaegi S.; Weksberg R.; Bassett A.S.

22q11.2 deletion syndrome and schizophrenia
pp. 131-131(1)
Authors: Bassett A.; Hodgkinson K.; Chow E.; Scutt L.; Weksberg R.

A linkage study of chromosome 22q in sib-pairs with schizophrenia
pp. 131-132(2)
Authors: Murphy K.C.; Williams N.M.; Cardno A.G.; Jones L.A.; Holmans P.; McGuffin P.; Owen M.J.

Chromosome 22q11 deletions--an under-recognized cause of idiopathic learning disability?
pp. 132-132(1)
Authors: Murphy K.C.; Jones R.G.; Griffiths E.; Thompson P.W.; Owen M.J.

The behavioural phenotype in velo-cardio-facial syndrome
pp. 132-132(1)
Authors: Murphy K.C.; Owen M.J.

Schizophrenia and other mental disorders in a population based sample of cleft palate patients
pp. 132-133(2)
Authors: Christensen K.; Mortensen P.B.

Evidence for linkage of psychosis and cerebral asymmetry to the centromeric region of the X chromosome
pp. 133-133(1)
Authors: Laval S.H.; Dann J.C.; Butler R.J.; Loftus J.; Rue J.; Leask S.J.; Bass N.; Vita A.; Nanko S.; Shaw S.; Peterson P.; Shields G.; Smith A.B.; Stewart J.; DeLisi L.E.; Crow T.J.

The HLA DRB1 gene locus in schizophrenia: an association study in 55 families with linkage to chromosome 6p
pp. 133-133(1)
Authors: Schwab S.G.; Knapp M.; Freymann J.; Albus M.; Lerer B.; Hallmayer J.; Maier W.; Wildenauer D.B.

Potential susceptibility genes in schizophrenia
pp. 134-134(1)
Authors: Wildenauer D.B.; Albus M.; Schwab S.G.; Hallmayer J.; Eckstein G.N.; Borrmann M.; Lichtermann D.; Zill P.; Hoenig S.; Lerer B.; Maier W.

Is there a gene for &unknown;schizophrenia&unknown;--where has the field of psychiatric genetics gone?
pp. 134-134(1)
Author: DeLisi L.E.

CAG repeats in schizophrenia: relationship with premorbid functioning--preliminary results
pp. 134-135(2)
Authors: Ayton A.K.; Morris A.; Tyson P.; Mortimer A.; Cottrell D.J.

Search for unstable DNA in schizophrenia
pp. 135-135(1)
Authors: Petronis A.; Vincent J.B.; Paterson A.D.; Bassett A.S.; Honer W.G.; Gottesman I.I.; Torrey E.F.; Meltzer H.Y.; Lieberman J.; Kennedy J.L.

Genomic CAG repeat expansions in schizophrenic patients from East Yorkshire
pp. 135-135(1)
Authors: Tyson P.J.; Morris A.C.; Sivagnanasundaram S.; Gaitonde E.; Mollon J.; Hunt D.; Mortimer A.

Endogenous retroviruses--a potential link between the genetic and environmental components of schizophrenia
pp. 135-136(2)
Authors: Stanley Neuropathology Consortium; Yolken R.H.; Leister F.; Yee F.; Johnston N.; Karlsson H.; Viscidi R.; Torrey E.F.

Serial analysis of gene expression of brain tissue from individuals with schizophrenia and bipolar disorder
pp. 136-136(1)
Authors: Stanley Neuropathology Consortium; Sun Y.; Yolken R.H.

Genomic differential display: a new approach for finding genes involved in schizophrenia
pp. 136-136(1)
Authors: Smith C.; Broude N.; Mapel S.; Graber J.; Lewis M.

Dimensions of psychosis in affected sibling pairs
pp. 136-137(2)
Authors: Cardno A.G.; Jones L.A.; Murphy K.C.; Sanders R.D.; Asherson P.; Owen M.J.; McGuffin P.

Premorbid IQ in patients with functional psychosis and their first degree relatives
pp. 137-137(1)
Authors: Gilvarry C.M.; Takei N.; Russell A.; Rushe T.; Hemsley D.; Murray R.M.

Distinctive patterns of verbal/non-verbal memory & intellectual ability in familial schizophrenia
pp. 137-137(1)
Authors: Mockler D.M.; Murray R.M.; Sigmundsson T.; Frangou S.; Sharma T.

Cognitive impairment and genetic risk in familial schizophrenia: assessment of performance on the mini-mental state examination (MMSE)
pp. 137-138(2)
Authors: Roberts S.A.; Scutt L.; Bassett A.S.; Honer W.G.; Chow E.

Spatial working memory and strategy formation in schizophrenic patients and their first degree relatives
pp. 138-138(1)
Authors: Toulopoulou T.; Morris R.G.; Murray R.M.

Planning strategies during trail-making test performance in schizophrenics and healthy relatives
pp. 138-138(1)
Authors: Wolwer W.; Falkai P.; Streit M.; Gaebel W.

Linkage of eye tracking dysfunction to DNA-markers on chromosome 6p21 in schizophrenia
pp. 138-139(2)
Authors: Arolt V.; Lencer R.; Schurmann M.; Purmann S.; Krecker K.; Schwinger E.

Eye tracking dysfunction in first degree relatives of schizophrenics and depressive patients
pp. 139-139(1)
Authors: Flechtner K.-M.; Steinacher B.; Helle M.; Mackert A.

Eye-tracking dysfunctions--A biobehavioral marker of susceptibility to schizophrenia
pp. 139-139(1)
Authors: Obuchowski M.; Cornblatt B.

Thalamic volumes in patients with schizophrenia, healthy siblings and normal controls
pp. 139-140(2)
Authors: Staal W.G.; Hulshoff Pol H.E.; Schnack H.G.; van der Schot A.; Gispen-de Wied C.C.; Hijman R.; Kahn R.S.

Genetic predisposition to psychosis as an echo of the speciation event
pp. 140-140(1)
Author: Crow T.J.

Schizophrenia: the illness that made us human
pp. 140-140(1)
Author: Horrobin D.F.

Characterization of retroviral sequences isolated from a monozygotic twin pair discordant for schizophrenia using RDA
pp. 140-141(2)
Authors: Klempan T.A.; Deb P.; O'Reilly R.L.; Torrey E.F.; Singh S.M.

Association of sex chromosome anomalies with childhood-onset psychotic disorders
pp. 141-141(1)
Authors: Kumra S.; Krasnewich D.; Rapoport J.L.

A family study of psychiatric morbidity in a sample of bipolar patients showing increased risk of schizophrenia
pp. 141-141(1)
Authors: Valles V.; Van Os J.; Guillamat R.; Gutierrez B.; Rosa A.; Campillo M.; Fananas L.

Mechanism of peripheral noradrenergic stimulation by clozapine
pp. 143-143(1)
Authors: Elman I.; Goldstein D.S.; Holmes C.; Pickar D.; Folio J.; Adler C.; Breier A.

Cognitive improvements on clozapine: a two year follow-up study
pp. 143-143(1)
Authors: Mortimer A.M.; Tyson P.; Dye S.

Introduction of clozapine in Belgium
pp. 143-144(2)
Authors: Peuskens J.; De Hert M.; Demeulenaere F.

Is clozapine more effective than conventional neuroleptics in schizophrenia?--a systematic cochrane review
pp. 144-144(1)
Authors: Wahlbeck K.; Cheine M.; Essali A.; Rezk E.

Elective combined ECT and clozapine therapy in blood test refusers
pp. 144-144(1)
Authors: James D.V.; Gray N.S.

Correlation of the therapeutic and toxic actions of risperidone therapy with plasma concentrations of risperidone and 9-OH-Risperidone
pp. 144-145(2)
Authors: Cock N.; Lambert T.; Ilett K.

Risperidone in the treatment of behavioral disturbances in dementia
pp. 145-145(1)
Authors: De Deyn P.; Lemmens P.; De Smedt G.

Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia
pp. 145-145(1)
Authors: Katz I.; Brecher M.; Clyde C.; Napolitano J.

Treatment of the symptoms of schizophrenia: a meta-analysis comparing risperidone with other antipsychotics
pp. 146-146(1)
Authors: Lemmens P.; Van Baelen B.; Brecher M.

The effects of risperidone on attention & motor function in schizophrenia
pp. 146-146(1)
Authors: Mockler D.M.; Gill S.; Soni W.; Morris R.G.; Sharma T.

The effects of risperidone on verbal fluency & executive function in schizophrenia
pp. 146-146(1)
Authors: Mockler D.M.; Gill S.; Soni W.; Morris R.G.; Sharma T.

The effects of risperidone on memory function in schizophrenia
pp. 147-147(1)
Authors: Mockler D.M.; Gill S.; Soni W.; Morris R.G.; Sharma T.

Comparative efficacy of clozapine and risperidone in treatment refractory schizophrenia
pp. 147-147(1)
Authors: Sharif Z.A.; Raza A.; Ratakonda S.; Kirschner T.; Miller C.E.; Gorman J.M.

Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders
pp. 147-147(1)
Authors: Thomas A.; Grainger D.; Andersen S.; Tollefson G.

Treatment failure with risperidone: can olanzapine be an alternative therapy?
pp. 148-148(1)
Authors: Wimmer P.; Belmaker R.H.; Schneidman M.; Treves I.; Sapir M.; Dossenbach M.

An open-label trial of olanzapine in a community mental health service
pp. 148-148(1)
Authors: Flynn S.W.; Atlman S.; Sladen-Dew N.; Honer W.G.

Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia and other psychotic disorders
pp. 148-149(2)
Authors: Hamilton S.H.; Genduso L.A.; Revicki D.A.

Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial
pp. 149-149(1)
Authors: Hamilton S.H.; Revicki D.A.; Genduso L.A.; Tollefson G.D.

Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents
pp. 149-149(1)
Authors: Kumra S.; Jacobsen L.K.; Rapoport J.L.

High dose olanzapine in treatment resistant schizophrenia
pp. 149-150(2)
Author: Launer M.A.

Efficacy of a 12 week trial of olanzapine in treatment refractory schizophrenia or schizoaffective disorder
pp. 150-150(1)
Authors: Ratakonda S.; Miller C.E.; Gorman J.M.; Sharif Z.A.

Olanzapine compared to fluphenazine in the treatment of acute schizophrenia
pp. 150-150(1)
Authors: Mimica N.; Dossenbach M.; Friedel P.; Folnegovic-Smalc V.; Makaric G.; Jakovljevic M.; Uglesic B.

Olanzapine versus risperidone and haloperidol in treatment of schizophrenia
pp. 150-151(2)
Authors: Jone B.; Tollefson G.

Olanzapine versus haloperidol in the treatment of first episode psychosis
pp. 151-151(1)
Authors: Sanger T.M.; Lieberman J.A.; Tohen M.; Tollefson G.D.

Olanzapine in the treatment of schizoaffective disorder
pp. 151-151(1)
Authors: Tran P.; Lu Y.; Sanger T.; Beasley C.; Tollefson G.

Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders
pp. 151-152(2)
Authors: Reams S.G.; Sanger T.M.; Beasley C.M.

Olanzapine vs. placebo in rapid-cycling bipolar disorder
pp. 152-152(1)
Authors: Sanger T.M.; Tohen M.; Tollefson G.D.; Jacobs T.; David S.

Olanzapine vs placebo in the treatment of acute mania
pp. 152-152(1)
Authors: Sanger T.M.; Tohen M.; Tollefson G.D.; McElroy S.L.; Greaney M.G.; Toma V.

Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol
pp. 152-153(2)
Authors: Canadian Cognition and Outcome Study Group; Purdon S.E.

Prolactin levels in olanzapine versus typical and atypical antipsychotics
pp. 153-153(1)
Authors: David S.; Crawford A.M.; Breier A.

Sertindole: targeting the optimal dosage for the treatment of schizophrenic patients
pp. 153-153(1)
Authors: Wehnert A.; Stilwell C.

A randomised controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia
pp. 153-154(2)
Authors: Mulholland C.; Lynch G.; King D.J.; Cooper S.J.

Long term treatment with &unknown;seroquel&unknown;: results of a multinational study of patient satisfaction and acceptability
pp. 154-154(1)
Authors: Kalali A.H.; Langham S.J.; Hurst B.C.; Hellewell J.S.E.

&unknown;Seroquel&unknown;&unknown;: an effective atypical antipsychotic with no greater EPS than placebo across the full dose range
pp. 154-154(1)
Authors: Hellewell J.S.E.; Hands D.C.; McKellar J.

Seroquel&unknown;: evidence for efficacy in the treatment of hostility and aggression
pp. 154-155(2)
Authors: Hellewell J.S.E.; Cameron-Hands D.; Cantillon M.

Chlorpromazine versus placebo for the treatment of schizophrenia: a symstematic review
pp. 155-155(1)
Authors: Thornley B.; Adams C.E.; Awad A.G.

Acute and long-term efficacy and safety of aripiprazole: a new atypical antipsychotic
pp. 155-155(1)
Authors: Petrie J.L.; Saha A.R.; McEvoy J.P.

Changes in psychopharmacological treatment strategies in schizophrenia--inpatient treatment 1989 vs. 1995
pp. 155-156(2)
Authors: Kurz M.; Hausmann A.; Honeder M.; Kemmler G.; Kurzthaler I.; Walch T.; Wechdorn H.; Fleischhacker W.W.

Negative symptoms and quality of life in schizophrenia-response to low dose neuroleptic: lessons from a clinical trial
pp. 156-156(1)
Authors: Canadian Remoxipride Study and the Canadian Remoxipride Group; Awad A.G.; Lapierre Y.D.; Angus C.; Rylander A.

An audit of the use of high dose neuroleptics in treating schizophrenia
pp. 156-156(1)
Authors: Tyson P.J.; Mortimer A.; Wheeler J.A.

Does participation in clinical trials prolong hospitalization?
pp. 156-157(2)
Authors: Bark N.M.; Da Silva-Siegel D.; Lewis J.

Negative symptoms improved by CSF filtration in a case of recent onset schizophrenia
pp. 157-157(1)
Authors: Bechter K.; Herzog S.; Schreiner V.; Wollinsky K.-H.; Schuttler R.

Zuclopenthixol acetate in psychiatric emergencies: looking for evidence from clinical trials
pp. 157-157(1)
Authors: Coutinho E.; Fenton M.; Adams C.E.; Campbell C.

Differential treatment effects of amisulpride versus flupentixol on latent dimensions of depressive and negative symptoms in acute schizophrenia
pp. 157-158(2)
Authors: Muller M.J.; Wetzel H.; Benkert O.

Glycine and D-cycloserine adjuvant pharmacotherapy for treatment-resistant schizophrenia
pp. 158-158(1)
Authors: Heresco-Levy U.; Javitt D.C.; Ermilov M.; Mordel C.

Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia
pp. 158-158(1)
Authors: Shah S.; Vankar G.K.; Telang S.D.; Ramchand C.N.; Peet M.

Muscarinic agents: a new approach to the treatment of psychosis
pp. 158-159(2)
Authors: Shannon H.E.; Bymaster F.P.; Bodick N.W.; Offen W.W.; DeLapp N.C.; Perry K.W.; Rasmussen K.; Ward J.S.; Whitesitt C.A.; Fink-Jensen A.; Olesen P.; Rasmussen T.; Sheardown M.; Swedberg M.; Sauerberg P.

Tips: early detection and treatment of first episode psychosis
pp. 159-159(1)
Authors: McGlashan T.H.; Vaglum P.; Johannessen J.O.; Larsen T.K.; Friis S.; Melle I.; Simonsen E.; Haahr U.; Rund B.

Early intervention and the course of schizophrenia
pp. 159-159(1)
Authors: Linszen D.H.; Dingemans P.M.A.J.; Lenior M.A.

Pre-psychotic intervention in schizophrenia: a stitch in time?
pp. 160-160(1)
Authors: McGorry P.D.; Yung A.R.; Phillips L.; Adlard S.; Hallgren M.; Patton G.; Hearn N.

The effects of atypical antipsychotic drugs on cognitive functioning in schizophrenia
pp. 160-160(1)
Authors: McGurk S.R.; Meltzer H.Y.

Medication algorithms for schizophrenia
pp. 160-160(1)
Authors: Miller A.L.; Chiles J.A.; Rush A.J.; Crismon M.L.; Toprac M.G.; Shores-Wilson K.L.

Double-blind placebo controlled trial of N-3 polyunsaturated fatty acids as an adjunct to neuroleptics
pp. 160-161(2)
Authors: Peet M.; Mellor J.

Off-label use of antipsychotic drugs
pp. 161-161(1)
Authors: Hummer M.; Koller D.; Hofer A.; Ulmer H.; Fleischhacker W.W.

Variables influencing outpatients compliance
pp. 161-161(1)
Authors: Eder U.; Koller D.; Hummer M.; Kurzthaler I.; Ulmer H.; Fleischhacker W.W.

Compliance in long-term treatment of schizophrenia
pp. 161-162(2)
Authors: Linden M.; Godemann F.

Fluoxetine treatment of de novo obsessive-compulsive symptoms in schizophrenia after clozapine treatment
pp. 162-162(1)
Authors: Makaric G.; Folnegovic-Smalc V.; Mimica N.; Folnegovic Z.

A comparison of treatment response between early- and adult-onset schizophrenia
pp. 162-162(1)
Authors: Honer W.G.; Kopala L.C.; Smith G.N.; Flynn S.W.; Fredrikson D.H.; Good K.P.; Altman S.; MacEwan G.W.

Hemodynamic changes in schizophrenic patients who received electroconvulsive therapy
pp. 162-163(2)
Authors: Lee S.-M.; Yip P.-K.; Jeng J.-S.; wen-kor C.; Ming C.

Efficacy of ECT in chronic aggressive behavior in schizophrenic/schizoaffective disorder inpatients
pp. 163-163(1)
Authors: Miller C.E.; Sharif Z.A.

Efficacy and safety of combining ECT and clozapine in patients with treatment refractory schizophrenia
pp. 163-163(1)
Authors: Sharif Z.A.; Raza A.; Ratakonda S.; Miller C.E.; Gorman J.M.

The effectiveness of cognitive therapy with coping training for persistent auditory hallucinations in an out-patient population
pp. 163-164(2)
Authors: Jenner J.A.; van de Willige G.; Wiersma D.

A cognitive training programme for schizophrenic patients
pp. 164-164(1)
Authors: Rund B.R.; Borg N.C.

A randomized controlled trial of cognitive behaviour therapy in the management of treatment-resistant schizophrenia
pp. 164-164(1)
Authors: Sensky T.; Siddle R.; O'Carroll M.; Scott J.; Turkington D.; Kingdon D.; Dudley R.; McPhillips M.; Johns C.; Scott J.L.; Barnes T.R.E.

A randomised control trial of individual neurocognitive remediation: the effects on cognitive deficits & general functioning
pp. 164-164(1)
Authors: Wykes T.; Reeder C.; Corner J.; Williams C.; Everitt B.

Different patterns of D₂/D₂-like receptor blockade in the temporal cortex and the striatum by typical antipsychotics: an ¹²³I-epiderpride spet study
pp. 165-165(1)
Authors: Bigliani V.; Mulligan R.S.; Acton P.D.; Gacinovic S.; Ell P.J.; Kerwin R.W.; Pilowsky L.S.

D2-density, personality traits, and negative symptoms of schizophrenia
pp. 165-165(1)
Author: Farde L.

(¹¹C)-N-methylspiperone pet detects different levels of dopamine D₂ receptor occupancy of an atypical neuroleptic than (¹¹C)-raclopride pet
pp. 165-166(2)
Authors: Hagberg G.; Gefvert O.; Bergstrom M.; Wieselgren I.-M.; Lindstrom L.; Wiesel F.-A.; Langstrom B.

Striatal dopamine D2 receptor occupancy in patients treated with olanzapine
pp. 166-166(1)
Authors: Raedler T.J.; Knable M.B.; Lafargue T.; Pickar D.; Weinberger D.R.

Olanzapine: antidopaminergic and memory effects in mice
pp. 166-166(1)
Authors: Rasmussen T.R.; Swedberg M.D.B.; Bymaster F.P.

In vivo effects of olanzapine on radioligand binding, dopamine D2 autoreceptor blockade, agonist-induced in vivo phosphoinositide hydrolysis and neurotransmitter release
pp. 166-167(2)
Authors: Zhang W.; Perry K.W.; Bymaster F.P.

D2 dopamine receptor upregulation is associated with poor treatment response and extrapyramidal side effects in schizophrenia: a follow-up study with¹²³ I-IBZM SPECT in the drug-naive state and after neuroleptic treatment
pp. 167-167(1)
Authors: Schroder J.; Bubeck B.; Silvestri S.; Karr M.; Demisch S.; Sauer H.

Relationships between dopamine-D2 receptor occupancy and dopa decarboxylase activity. A pet-study in neuroleptic treated patients with schizophrenia
pp. 167-167(1)
Authors: Wiesel F.-A.; Bela M.; Gefvert O.E.; Hagberg G.; Langstrom B.; Trolin G.; Valind S.

Are the new antipsychotics atypical with respect to D₂ receptor occupancy in vivo?
pp. 167-168(2)
Author: Nyberg S.

Lack of psychopharmacological signature to the selective D₄ antagonist L 745,870 as evaluated ethologically
pp. 168-168(1)
Authors: Clifford J.J.; Waddington J.L.

An enhancement of latent inhibition by selective CCK antagonists
pp. 168-168(1)
Authors: Gracey D.J.; Bell W.R.; King D.J.

CCK receptors in the brain as targets for new antipsychotic drugs
pp. 168-169(2)
Author: Lindefors N.

Effects of the dopamine receptor antagonist raclopride and the serotonin receptor antagonist LY 53857 alone and in combination on extracellular recordings of substantia nigra reticulata neurons of the rat brain
pp. 169-169(1)
Authors: Bruggeman R.; Heeringa M.J.; Westerink B.H.C.; Timmerman W.

Serotonin 5-HT 1a receptors modulate hippocampal reactivity to afferent stimulation
pp. 169-169(1)
Authors: Levkovitz Y.; Segal M.

Effects of atypical antipsychotic drugs on dopamine output in the shell and the core of the nucleus accumbens: role of 5-HT_2A and ₁-adrenoceptor antagonism
pp. 170-170(1)
Authors: Marcus M.M.; Nomikos G.G.; Svensson T.H.

Comparison of 5-HT_2A antagonists M100907 and ritanserin in preclinical models of antipsychotic activity
pp. 170-170(1)
Authors: Sorensen S.M.; Martin P.; Hitchcock J.M.

Antipsychotic drug affinities for the human brain alpha2 adrenoceptor subtypes
pp. 170-171(2)
Authors: Reynolds G.P.; Blake T.-J.; Tillery C.E.

Typical antipsychotics lead to 5-HT_2A receptor blockade in vivo in schizophrenic patients: initial single photon emission tomography (spet) findings
pp. 171-171(1)
Authors: Travis M.J.; Busatto G.F.; Pilowsky L.S.; Mulligan R.; Gacinovic S.; Acton P.D.; Costa D.C.; Mertens J.; Terriere D.; Ell P.J.; Kerwin R.W.

Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia
pp. 171-171(1)
Authors: Brown A.S.; Gewirtz G.; Harkavy-Friedman J.; Cooper T.; Brebion G.; Amador X.F.; Malaspina D.; Gorman J.M.

Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia?
pp. 172-172(1)
Authors: Joffe G.; Nyberg P.; Gross A.; Appelberg B.

Risperidone treatment causes altered d-fenfluramine evoked serotonergic responses in schizophrenia similar to clozapine treatment
pp. 172-172(1)
Authors: Jones H.; Curtis V.A.; Wright P.J.; Lucey J.V.

Protein kinase c-mediated desensitisation of the motor effects of psychodysleptic sigma1 drugs: clinical perspectives in schizophrenia
pp. 172-173(2)
Authors: Monnet F.P.; Villemain F.; Morin-Surin M.P.

Time course of rCBF changes after acute haloperidol in patients with schizophrenia
pp. 173-173(1)
Authors: Lahti A.C.; Holcomb H.H.; Weiler M.A.; Medoff D.; Tamminga C.A.

Immediate and long term effects of risperidone on cerebral metabolism in schizophrenia
pp. 173-173(1)
Authors: Ngan E.T.C.; Lane C.J.; Liddle P.F.

Clozapine changes mitochondria in nervous tissue culture of human embryos
pp. 173-173(1)
Authors: Orlovskaya D.D.; Buravlev V.M.; Uranova N.A.

Neuropsychological case studies of tardive dyskinesia
pp. 175-175(1)
Author: Collinson S.L.

Dyskinesia and pulmonary function--a study of men born in 1933
pp. 175-175(1)
Authors: Nilsson A.; Rosengren A.; Horrobin D.F.; Wilhelmsen L.

The treatment of tardive dyskinesia: a systematic review and meta-analysis
pp. 175-176(2)
Authors: Soares K.V.; McGrath J.J.

What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?
pp. 176-176(1)
Authors: Tamura R.N.; Beasley C.M.; Dellva M.A.; Glazer W.M.; Morgenstern H.; Tollefson G.D.

Neurocognitive deficits, symptoms, neuroleptic side-effects and quality of life in schizophrenia
pp. 176-176(1)
Authors: Awad A.G.; Heslegrave R.J.; Voruganti L.N.P.

Computer-aided assessment of medication induced parkinsonism in first episode psychoses
pp. 176-177(2)
Authors: Berger G.; Hofer H.; Merlo M.C.G.

Six year follow-up study of chronic akathisia in a schizophrenic inpatient population
pp. 177-177(1)
Authors: Halstead S.M.; Barnes T.R.E.; Hennessy R.E.; Goswami U.

The spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia
pp. 177-177(1)
Authors: Kumra S.; Jacobsen L.K.; Rapoport J.L.

GATES: a new instrument for the clinical and research assessment of neuroleptic-induced movement disorders
pp. 177-178(2)
Author: Lambert T.J.R.

Differential regulation of direct and indirect striatal outflow pathways by ampa/kainate receptor modulators
pp. 178-178(1)
Authors: Healy D.J.; Randolph E.; Meador-Woodruff J.H.

Left fronto-parietal dysfunction of gaba-a receptors and movement-related potentials in akinetic catatonia: a combined spect- and MRP study
pp. 178-178(1)
Authors: Northoff G.; Steinke R.; Krug M.; Cervenka C.; Pfennig A.; Otto H.; Bogerts B.

Vulnerability to involuntary movements over a lifetime of severe schizophrenia approaches 100% in intimate association with frontal lobe dysfunction
pp. 178-179(2)
Authors: Quinn J.; Meagher D.; Murphy P.; Kinsella A.; Mullaney J.; Waddington J.L.

Visuo-manual testing in the diagnosis of extra-pyramidal side effects of anti-psychotic drugs
pp. 179-179(1)
Authors: Weiser M.; Davidson M.; Schnaider-Beeri M.; Hocherman S.

Weight gain induced by olanzapine
pp. 179-179(1)
Authors: Wei E.; Danzl C.; Hummer M.; Kemmler G.; Lindner C.; Reinstadler K.; Fleischhacker W.W.

Neurological signs in patients with a first episode of psychosis and healthy controls
pp. 179-180(2)
Authors: Boks M.P.M.; Knegtering H.; Haaxma R.; van den Bosch R.J.

Soft signs in first episode schizophrenia: evidence for trait and state processes influencing neurological performance
pp. 180-180(1)
Authors: Browne S.; Clarke M.; Gervin M.; Waddington J.L.; Larkin C.; O'Callaghan E.

Deterioration of soft neurological signs in chronic schizophrenic patients: a longitudinal panel study
pp. 180-180(1)
Authors: Chen E.Y.H.; Lau B.S.T.

Soft neurological signs and sustained attention impairment in schizophrenia
pp. 180-181(2)
Authors: Chen E.Y.H.; Lam L.C.W.; Wilkins A.

Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and normals
pp. 181-181(1)
Authors: Flyckt L.; Sydow O.; Bjerkenstedt L.; Edman G.; Rydin E.; Wiesel F.-A.

Neurological abnormality in schizophrenic patients and siblings
pp. 181-181(1)
Authors: Ismail B.T.; Cantor-Graae E.; McNeil T.F.

Minor physical anomalies in schizophrenic patients and siblings: how effective is the waldrop scale?
pp. 181-182(2)
Authors: Ismail B.T.; Cantor-Graae E.; McNeil T.F.

Differential presentation of soft neurological signs and schizophrenic symptoms in relation to sex and age of onset
pp. 182-182(1)
Authors: Lam L.C.W.; Chen E.Y.H.; Nguyen D.G.H.; Chen R.Y.L.

Are neurological soft signs related to neuroleptic side effects?
pp. 182-182(1)
Authors: Schroder J.; Jahn T.; Hubmann W.; Niethammer R.; Karr M.; Mohr F.; Cohen R.

Neurological soft signs in prodromal patients
pp. 182-183(2)
Authors: Velakoulis D.; Yung A.; Brewer W.; McGorry P.; Pantelis C.

Neurological soft signs and positive and negative symptoms in the early course of schizophrenia
pp. 183-183(1)
Authors: Weimer D.; Bachmann S.; Schroder J.; Kratz B.; Pantel J.; Resch F.; Mundt C.

Gender differences in the psychopathology of first episode schizophrenia
pp. 185-185(1)
Authors: Brewin J.; Glazebrook C.; Cantwell R.

Mediating effects of gender differences at 3 year follow-up in a cohort of first onset psychoses
pp. 185-185(1)
Authors: Croudace T.J.; Amin S.; Singh S.; Jones P.; Harrison G.

Sex differences in presentations of patients with first episode schizophrenia
pp. 185-186(2)
Authors: Drake R.J.; Akhtar S.; Haley C.; Faragher B.; Lewis S.W.

Are symptoms observed differently in male and female first-episode patients?
pp. 186-186(1)
Authors: Hambrecht M.; Hafner H.

Sexual dysfunction and serum prolactin levels in patients using classical antipsychotics or risperidone
pp. 186-186(1)
Authors: Knegtering H.; Boks M.; ten Brink C.

Sex and neuroendocrine differences in response to treatment with olanzapine: a preliminary analysis
pp. 186-187(2)
Authors: Andersen S.; Cohen L.; Goldstein J.; Tohen M.; Tollefson G.

Gender and schizophrenia: clinical profiles
pp. 187-187(1)
Authors: Rodado J.; Rodado M.J.; Barcia D.

Cholinergic and serotonergic dysfunction in oestrogen deprived women: a clue to late on-set schizophrenia?
pp. 187-187(1)
Authors: van Amelsvoort T.; Abel K.; Robertson D.; Critchley H.; Daly E.; Xenitidis K.; Murphy D.G.M.

Oestrogen improves dysfunction of the frontocortico-striatal network (FCSN) during menopause
pp. 187-187(1)
Authors: Reveley M.A.; Dursun S.M.; Habibba M.A.; Al-Azzawi F.

Relationship between menstrual cycle and psychopathology in schizophrenics
pp. 187-188(2)
Authors: Bassitt D.P.; Ranieri M.A.; Louza Neto M.R.

Menstrual cycle changes in schizophrenia
pp. 188-188(1)
Authors: Kulkarni J.; de Castella A.; Thompson K.

Assessment of menstrual cycle phase in women with schizophrenia
pp. 188-188(1)
Authors: Kulkarni J.; de Castella A.; Thompson K.

Predicting quality of life in patients with schizophrenia with changes in symptomatology
pp. 189-189(1)
Authors: Bow-Thomas C.C.; Velligan D.I.; Miller A.L.

Relationship between quality of life and symptomatology in schizophrenia
pp. 189-189(1)
Authors: Summerfelt W.T.; Jayathilake K.; Meltzer H.

A comparison of subjective and objective evaluations of quality of life in schizophrenia
pp. 189-190(2)
Authors: Doyle M.; Flanagan S.; Browne S.; Clarke M.; Lydon D.; Larkin C.; O'Callaghan E.

Relationships between quality of life measures and clinical symptomatology in people with persistent schizophrenia
pp. 190-190(1)
Authors: Keks N.A.; Hope J.D.; Trauer T.

The shared social environment and psychiatric disorder: ecological or individual effect?
pp. 190-190(1)
Authors: van Os J.; Driessen G.; Gunther N.

Integrating quality of life assessment into consumer-focused research
pp. 191-191(1)
Authors: Welham J.L.; Haire M.; Stedman T.J.; Mercer D.

Perceived needs in patients with chronic schizophrenia: their relationship to negative symptoms and to insight
pp. 191-191(1)
Authors: Carroll A.; Mortimer A.

Schizophrenic patients' normative needs for care and perceived needs for care and support. Results 1 month after discharge from the psychiatric hospital
pp. 192-192(1)
Author: Kallert T.W.

Unmet needs for care in the community-what is required versus what is available
pp. 192-192(1)
Authors: Kumar T.M.; Mortimer A.M.; deSilva P.; Ellwood P.

The needs of parents with serious mental illness
pp. 192-193(2)
Authors: McGrath J.; Hearle J.; Jenner L.; Plant K.; Barkla J.

Structured needs assessment as an outcome measure in psychosis: a comparison of two contrasting services
pp. 193-193(1)
Authors: Murray V.; Walker H.W.; Mitchell C.; Pelosi A.J.

Satisfaction with mental health services among families of patients with schizophrenia in a community based psychiatric service--before and after the introduction of the care program approach
pp. 193-193(1)
Authors: Ayton A.K.; Tyson P.; Mortimer A.

Core negative symptoms and social functioning: West London first-episode schizophrenia study
pp. 193-194(2)
Authors: Chapman M.; Hutton S.; Duncan L.-J.; Puri B.K.; Joyce E.M.; Barnes T.R.E.

The WPA global programme against stigma and discrimination because of schizophrenia
pp. 194-194(1)
Authors: Fleischhacker W.W.; Hafner H.; Leff J.; Lopez-Ibor J.J.; Maj M.; Sartorius N.; Stefanis C.N.; Warner R.; Wig N.N.

Does psychoeducation change the concept of illness of schizophrenic patients
pp. 194-194(1)
Authors: Hofer E.; Amering M.; Windhaber J.; Wancata J.; Eberstaller M.

Depressive symptoms and social functioning in chronic schizophrenia
pp. 194-195(2)
Authors: Mulholland C.; Wilson C.; McCrum B.; MacFlynn G.

Socio-environmental variables in schizophrenia
pp. 195-195(1)
Authors: Mallett M.R.; Bhugra D.; Hutchinson G.; Burnett R.; Leff J.

Neurobiological variables at presentation and compliance with antipsychotic medication at six months: West London first-episode schizophrenia study
pp. 195-196(2)
Authors: McPhillips M.A.; Hillier R.; Hutton S.; Duncan L.-J.; Puri B.K.; Joyce E.M.; Barnes T.R.E.

Family factors related to relapse into schizophrenia
pp. 196-196(1)
Authors: Boye B.; Munkvold O.G.; Bentsen H.; Notland T.H.; Malt U.

Improving the outcome of social skills training by the inclusion of specific cognitive behaviour therapy methods and topics: a multi-centre study
pp. 196-196(1)
Authors: Roder V.; Reisch T.; Brenner H.D.

Characteristics of the new long-stay population in an acute psychiatric hospital in inner Melbourne
pp. 196-197(2)
Authors: Smith D.; Harvey C.; Richards J.; Pantelis C.

Sexual behavior among inpatients with schizophrenia
pp. 197-197(1)
Authors: Buckley P.F.; Robben T.; Friedman L.; Hyde J.; Winterich D.

The cochrane schizophrenia group: producing, maintaining and disseminating reviews of care
pp. 197-197(1)
Author: Adams C.E.

Isolation but not enriched rearing of rats impairs prepulse inhibition of startle: relevance to schizophrenia
pp. 199-199(1)
Author: Geyer M.A.

Bilateral lesions of the laterodorsal tegmental nucleus disrupt prepulse inhibition of the acoustic startle reflex in rats
pp. 199-199(1)
Authors: Jones C.K.; Shannon H.E.

Evidence for an alternation in the balance between dopamine and serotonin transmission in the medial prefrontal cortex of the conscious rat following repeated ketamine administration
pp. 199-200(2)
Authors: O'Connor W.T.; Lindefors N.

In vivo dopamine receptor gene transfer using an adenoviral vector
pp. 200-200(1)
Authors: Wong A.H.C.; Knapp M.; Van Tol H.H.M.

The cochrane schizophrenia group: producing, maintaining and disseminating reviews of care
pp. 200-200(1)
Author: Adams C.E.

A comparison between schizophrenia and temporal lobe epilepsy: a proton magnetic resonance spectroscopy study
pp. 200-201(2)
Authors: Maier M.; Ron M.A.; Mellers J.; Toone B.; Trimble M.

Cognitive development in schizophrenia: some heuristic offerings from the study of abnormal cognitive development in epilepsy
pp. 201-201(1)
Authors: Done D.J.; Leask S.J.; Harvey P.; Ross E.; Tookey P.; Crow T.J.

Schizophrenia and epilepsy; alternative responses to brain injury of maldevelopment
pp. 201-201(1)
Authors: Stevens J.R.; Denney D.

A neuropsychological comparison of schizophrenia and the schizophrenia-like psychoses of epilepsy
pp. 201-202(2)
Authors: Mellers J.D.C.; Toone B.K.; Lishman W.A.

Multivariate analysis of body size and shape in schizophrenia
pp. 202-202(1)
Authors: Reilly J.L.; Lane A.; Kinsella A.; Larkin C.; O'Callaghan E.

The primary care of patients with schizophrenia
pp. 203-203(1)
Authors: Burns T.; Kendrick T.; Cohen A.

Olanzapine versus fluphenazine--6 weeks treatment of anxiety symptoms during acute schizophrenia
pp. 203-203(1)
Authors: Dossenbach M.; Jakovljevic M.; Folnegovic V.; Uglesic B.; Dodig G.; Friedel P.; Hotujac L.

On the ability of schizophrenic patients to learn control of inter-hemispheric slow potential negativity
pp. 203-203(1)
Authors: Gruzelier J.; Wild J.; Hardman E.; Zahman R.; Hirsch S.

Visualisation of dopamine-2 receptor blockade in psychotic patients treated with zotepine
pp. 204-204(1)
Authors: Willeit M.; Barnas C.; Tauscher J.; Kufferle B.; Krenn P.; Asenbaum S.; Brucke T.; Kasper S.

A placebo-controlled trial of olanzapine in psychotic or non-psychotic acute mania
pp. 204-204(1)
Authors: Toben M.; Zarate C.; Sanger I.M.

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration
pp. 204-205(2)
Authors: Jones B.; Crawford A.M.K.; Beasley C.M.; Tollefson G.D.

Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
pp. 205-205(1)
Authors: Tran P.V.; Tollefson G.D.; Andersen S.W.; Kuntz A.J.; Hamilton S.H.

A blinded trial on the course and relationship of depressive symptoms in schizophrenia
pp. 205-205(1)
Authors: Tollefson G.D.; Sanger T.M.